Level of compliance with a gluten free diet and nutritional status of adult’s patients with coeliac disease by ALVES, ELIZABETH
 UNIVERSITY OF ROEHAMPTON 
HEALTH SCIENCES RESEARCH CENTRE 
DEPARTMENT OF LIFE SCIENCES 
 
 
 
 
 
 
Level of compliance with a gluten free diet and nutritional status of adult’s 
patients with coeliac disease 
 
 
 
 
 
 
 
 
London 
 AUGUST/ 2015 
  
ELIZABETH SILVA FERREIRA ALVES 
 
 
 
 
 
 
 
Level of compliance with a gluten free diet and nutritional status of adult’s 
patients with coeliac disease 
 
 
 
 
 
 
 
 
London 
 AUGUST/ 2015 
 
Completed work for postgraduate course at 
Roehampton University presented as partial 
requirement for the degree of Master in Clinical 
Nutrition. 
!! ! 1!
 
 
 
 
 
ACKNOLEDGEMENT 
 
First, I would like to say a very big thank you to my supervisor Dr Yvonne 
Jeanes for her generous guidance, time, knowledge and suggestion 
throughout my dissertation. I would also like to express my sincere gratitude 
to the PhD student Dr Humayun Muhammad for giving me access to the data 
used in my project and for his total help and availability. To all professionals of 
Nutrition Department, all university staff and colleagues, thank you. To my 
dear family and friends thanks for always supporting me. 
 
 
 
 
 
 
 
 
 
!! ! 2!
Table of Contents  
1. List of tables and Figures..................................................................04 
2. Abstract...............................................................................................06 
3. Introduction………………………………………………………………..07 
4. Literature Review………………………………………………………....08 
4.1. Coeliac disease………………………………………………………..08 
4.2.  Gluten free diet………………………………………………………..09 
4.3. Dietary adequacy and celiac disease……………………………….11 
4.4. Gluten free products (GFPs)…………………...…………………….13 
4.5. Compliance with a gluten free diet…………………………………..15 
4.6. Aims…………………………………………………………...………..15 
5. Methods……………………………………………………..……………..17 
5.1. Design..……………………………………………………………..….17 
5.2. Sample…..…………………………..…………………………………17 
5.3. Materials………………………………………………………………..17 
5.4. Procedure…………………………………………………….………..19 
5.5. Ethics……………………………………………….…………………..20  
5.6. Statistical Analysis…………………………………………………….20  
6. Results………………………………………………………………..…….22 
6.1. Descriptive………………………………….………………………….22 
6.2. Compliance to gluten free diet…………………………………….…23  
6.3. Dietary intake………………………………………………..…………26 
6.4.  Nutrition status of the patients………………………………………29 
6.5. Symptoms before and after GFD adherence………………………31 
7. Discussion…………………………………………………………………34 
7.1. Compliance with gluten free diet…………………………………….34 
7.2. Dietary intake…………………………………………………………..38 
7.3. Nutrition status of the CD patient……………………………………42 
7.4. Symptoms before and after related to GFD adherence….……….45 
7.5. Implications and Limitations…………………………………....…….46 
7.6.  Future Research………………………………………………..…….47 
8. Conclusion…………………………………………………………………48 
9. References……………………………………………………….…..……49 
!! ! 3!
10. Appendixes:……………………………………………………………….65 
APPENDIX 01: Compliance questionnaires. 
APPENDIX 02: Food diaries form example. 
APPENDIX 03: Ethical approval letters 
APPENDIX 04: Descriptive data 
APPENDIX 05: Descriptive data by compliance groups. 
APPENDIX 06: Data of level compliance, percentage of GFD on prescription, 
and frequency of consumption of products containing gluten. 
APPENDIX 07: Difference test in age, gender, ethnicity, weight, GFD on 
prescription and frequency of consumption of products containing gluten on 
diet between compliant and non-compliant. 
APPENDIX 08: Dietary intake and meeting RIN-intake of micronutrients data. 
APPENDIX 09: Difference test in nutrients intake between groups 
APPENDIX 10: APPENDIX 09: Difference in micronutrients meeting RNI-
intake between groups. 
APPENDIX 11: Correlations analysis for BMI and fat, fibre and energy intake, 
data of mean BMI and differences in BMI between compliance groups. 
APPENDIX 12: Data of symptoms before and after GFD. 
APPENDIX 13: Data of types of symptoms mentioned 
 
 
 
 
 
!! ! 4!
List of tables 
Table 01. Mean and (SD) of demographic information, energy intake and BMI 
of compliant and non-compliant patients  
Table 02. Values of difference in age, gender, ethnicity, weight, GFD on 
prescription and frequency of consumption of products containing gluten on 
diet between compliance groups 
Table 03. Results of macronutrients, fibre and micronutrients intake, and fibre 
of CD patients: Mean and recommendation of nutrients intake 
Table 04. Difference between compliance groups related to macronutrients, 
micronutrients, fibre and energy density of fibre: median, range and p value 
Table 05. Difference between compliant and non-compliant patients related to 
meeting RNI-intake of fibre and micronutrients 
Table 06. Correlation between BMI and fat, fibre and energy intake  
Table 07. BMI mean and SD of compliant and non-compliant patients, and 
the difference in BMI between the two groups 
Table 08. Types of symptoms mentioned by compliant and non-compliant 
patients  
 
List of figures 
Figure 01. Frequency of consumption of products containing gluten in the 
diets of the patients 
Figure 02. Distribution percentage of GFD on prescription 
Figure 03. The percentages of meeting intake of fibre, vitamin B6 and B12, 
calcium, iron and total folate of the CD patients 
!! ! 5!
Figure 04. Result of correlations between BMI and energy intake  
Figure 05. Length of symptoms before GFD 
Figure 06. Symptoms after introduction of GFD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!! ! 6!
ABSTRACT 
Background:  A good compliance to gluten free diet is an important part of 
coeliac disease management, which requires total commitment on the part of 
patients, as prevents further complications related to the disease. This study 
aimed to verify the level of compliance with a gluten free diet and the 
nutritional status of patients with coeliac disease. 
Methods: A Coeliac Dietary Adherence Test was assessed in 86 adults’ 
patients with coeliac disease (63 female and 23 male, aged 19-64) who were 
on a GFD for more than 3 months. Dietary intake using 3-day food diary and 
BMI were also obtained and analysed. 
Results: Seventy-one patients were identified as compliant and 15 as non-
compliant. A higher percentage of non-compliant (46.7%) patients committed 
dietary transgression compared to compliant (22.5%). Percentage of 
compliant patients (33.8%) who reported did not receive gluten free diet on 
prescription was lower than non-compliant (40%). All patients had low intake 
of energy intake, protein, fibre, fibre energy density and high intake of 
carbohydrate, compared to Dietary Reference Intakes. Vitamin B12 was the 
only macronutrient according to the nutritional recommendation. High 
difference was found in fibre energy density between compliance groups 
(p=0.029). None of non-compliant met the RNI-intake of calcium, folate and 
fibre.  Both compliance groups were classified as overweight. BMI were highly 
correlated to energy intake (p=0.004), fat (p= p= 0.026) and fibre (p=0.041). It 
was found presence of symptoms in 82.6% of the all patients. 
Conclusion: Despite this study has found high percentage of compliant 
patients, presence of nutritional deficiency and persistent symptoms were 
verified amongst those patients. This shows that all facets of the disease, not 
only gluten avoidance, should be analysed when is addressing about the 
treatment of celiac disease. 
Key words: Celiac Disease, compliant and non-compliant, and Nutritional 
status. 
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1. INTRODUCTION 
Coeliac disease (CD) is known as an autoimmune response that occurs in the 
mucosa of small intestinal due to exposure to gluten-containing food, which 
consequently leads to atrophy of villous, inflammation and malabsorption 
(Norström et al., 2012). Although, once CD has indicated as an uncommon 
disorder, new screening researches have demonstrated that CD prevalence 
has increased and affects 1% of European population. However, many cases 
of CD continue undiagnosed (Capriles et al., 2009). CD is found in all age, but 
it has been detected commonly in adults (Lohi et al., 2007). CD pathogenesis 
ranges from genetic predisposition to environmental exposure, and its clinical 
presentation is varied. Since, it can result in malnutrition, and as well as, in 
gastrointestinal symptoms. Undetected cases of CD are characterized by 
atypical symptoms, which includes few or none gastrointestinal symptoms 
(Capriles et al., 2009; Mein and Ladabaum, 2004). The only Treatment 
accepted for CD is a strict gluten free diet (GFD), wherefore, it is natural to 
assume that after GFD introduction, patients have an recovery of the 
enteropathy and an improvement of absorptive area, which may lead to an 
adequate nutrients absorption (Ohlund et al., 2010). Furthermore, it was 
reported that patients treated effectively with a total GFD, they may obtain an 
excellent prognostic and likely live a normal life. A poor CD management or 
non-compliance with a GFD may lead to persistent symptoms, and 
consequently, to complications such as, malignancy and mortality (Bellini et 
al., 2011; Freeman et al., 2009). Nevertheless, many studies have 
investigated compliance with a GFD and shown that compliance with a GFD 
is not totally unanimous (Fabiani et al., 2000; Rashid et al., 2005; Comino et 
al., 2012). Compliance with GFD is important for the success of CD 
management and it depends on Patients, caregivers and experts of CD 
(Ohlund et al., 2010; Leffler et al., 2007).  
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2. Literature Review 
2.1. Coeliac disease 
Coeliac disease is a chronic condition that is described as an inflammatory 
enteropathy response to gluten ingestion in individuals who are genetically 
susceptible (Niewinski, 2008; Vincentini et al., 2011). Gluten is named as 
prolamin that is a protein fraction present in wheat, barley, rye and oats, in 
country like Australia. Gluten is named as prolamin that is a protein fraction 
present in wheat, barley, rye and oats, in country like Australia. The damage 
of small bowel mucosa is the major characteristic of CD (Planas et al., 2011). 
This impairment initiates first in the duodenum and later advances to the 
ileum. The impairment of small bowel mucosa occurs followed by progressive 
levels of villus damage and inflammation, which results in crypt hyperplasia 
induction (Eid et al., 2013). Villus loss and crypts hypertrophy leads to a 
chronic excess of fluids including the epithelial infiltration of T cells in the 
lumen of small bowel (Ciclitira et al., 2005; Eid et al., 2013; Du Pre et al., 
2015), and as well as, to a poor absorption of essential vitamins and minerals, 
such as, iron, vitamin B12, calcium, folic acid, (Edi et al., 2013). Clinical 
picture of CD ranges from asymptomatic to a typical presentation, and it relies 
on several factors including age, onset, duration and severity of the disease 
(Reilly and Green, 2012; Mazzone et al., 2011; Nachman et al., 2009). The 
symptoms when manifest consist of abdominal pain, diarrhoea, weight loss, 
fatigue and nausea (Sainsbury and Mullan, 2011). Therefore, CD is highly 
associated to anaemia, osteoporosis and neuropathy (Nachman et al., 2009; 
Addolorato et al., 2004) and when untreated can progressively causing 
infertility, osteopenia, venous thromboembolism, intestinal and bowel cancers, 
secondary hyperparathyroidism and other autoimmune complications (Eid et 
al., 2013; Krupa-Kozak, 2014; Norström et al., 2012; Ludvigsson et al., 2011). 
Asymptomatic CD includes a small intestine damaged, a serology positive 
and no symptoms (Mazzone et al., 2011; Nachman et al., 2009; Addolorato et 
al., 2004). 
Coeliac disease was once seen as childhood disease but it has been shown 
to affect young and elderly similarly (BIngley, 2004; Godfrey et al., 2010). It is 
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a worldwide disease affecting almost 1% of universal population with an 
occurrence of 6 per 100 children and 1 per 100 adults (Susanna and 
Prabhasankar, 2015). This has been demonstrated to be similar among adults 
population in United Kingdom, affecting approximately 1 in each 87 adults. 
Additionally, in Europe, cases of CD have increase significantly and it have 
also related to recent increase in mortality (Häuser et al., 2010; Leffler et al., 
2008; Godfrey et al., 2010). Although, CD is most common in Caucasians 
individuals, it is believed to be uncommon in East Asia, as well as, in central 
Africa. Furthermore, The increase prevalence of CD seems to be due to an 
extensive serological testing, and as well as, the highest level of recognition 
and awareness (Krupa-Kozak, 2014). Curiously, this increase in prevalence of 
CD is higher among women than men, in which 2 in each 8 females have CD 
in contrast to 1 in each 8 male. It is believed that this increase is associated to 
evidence that CD is mostly detected in men when they are at an older age 
(Gujral et al., 2012). When CD is suspected biopsy of small bowel is the 
standard method used to the final diagnosis, along with the biopsy of the 
duodenal. Recent serologic tests, such as, antibody testing, have been also 
included, and it has also shown to be an effective and highly sensitive method 
(Frulio et al., 2015; Godfrey et al., 2010). Antibody testing includes 
endomysial antibodies and transglutaminase. However, the first indication of 
CD presence may delay to appear (Norström et al., 2012). Currently, a 
rigorous gluten free diet (GFD) has proved to be the key treatment for CD. 
GFD is important and beneficial in the recovery of the small bowel function 
and structure (Niewinski, 2008). 
2.2. Gluten free diet (GFD) 
Avoidance of natural or processed foods containing gluten is undoubtedly the 
best description of a gluten free diet (Rajpoot and Makharia, 2013), since 
GFD is the only acceptable therapeutic treatment for patients with CD and it is 
for all life (Green et al., 2015; Bellini et al., 2011). This diet seems to improve 
clinical aspect of the disease by ameliorating clinical and laboratory 
parameters, attenuating symptoms, and probably avoiding the risk of long-
term complications (Sainsbury et al., 2013). Many important studies have 
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shown evidence that supports the positive effects of treatment with GFD in 
CD patients who have typical characteristics of CD (Nachman et al., 2009). A 
strict GFD has shown to normalize the small bowel mucosa, which is very 
important to a better functionality of gastrointestinal, including improvement of 
nutrients absorption, which means a better life for CKD patients (Frulio et al., 
2015; Akobeng and Thomas, 2008). However, a little recovery in the intestinal 
mucosa may occur in months or years depending on the patients and the 
disease state (Collin et al., 2004). In a prospective study with 57 CD adults’ 
patients and 83 control participants was shown the effects of GFD introduction 
in duodenal morphology. The findings demonstrated that after 4 years of GFD 
there was an improvement in villous area, as well as, a reduction of crypt 
measurement. However, this changes in morphometric indices was not 
associated with dietary compliance with a GFD but this was highly correlated 
to the anti-endomysial IgA antibody disappearance (Cummins et al., 2011). 
Additionally, a study in patients with urticarial and with celiac disease has 
reported that gluten free diet reduces clinical symptoms related to skin and 
intestine. Since the increase of mucosa permeability followed by passage of 
antigens may lead to lesions of urticarial. Therefore, recovery of the mucosa 
integrity with a strict GFD seems to improve skin symptomatology and then 
urticarial (Abenavoli et al., 2006). GFD has also shown to increase bone mass 
density or to maintain it stable in patients who follow GFD for at least 1 year. 
The results showed an improvement of bone mass density at the lumbar 
spine level in 52% of CD patients, at the femoral neck (46%), as well as, at 
the trochanter level (68%). Furthermore, as it was a 5-year follow-up study, 
the authors considered the outcomes as a positive response of CD patients to 
GFD (Kemppainen et al., 1999). Similarly, other studies have reported that 
strict GFD leads to a normal content of bone mineral and to a normal bone 
height, and as consequent, improvement of their body composition (Bardella 
et al., 2000). Other strong indication of GFD beneficial preventive effects in 
CD is related to malignancy. Study has shown that rates of malignancy tend 
to be higher among Individuals with untreated celiac disease compared to 
general population. This study has also shown when a patient is on a gluten 
free diet up to 5 years, their risk to lymphoma, and carcinoma of small bowel 
are relatively equal to general population (Haines et al., 2008). Concerning to 
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association between CD and other comorbidities, there is no significant 
studies showing the benefits of GFD treatment in patients with both diseases 
(Hill et al., 2005). Although, it has shown GFD effectiveness and benefits, 
studies have revealed that a significant percentage of patients do not respond 
positively to GFD, in terms of improvement of symptoms. A study has shown 
that almost 30% of individuals treated with GFD are not benefited with 
improvement of symptoms that are associated to CD. This non-responsive 
coeliac disease is characterized by the continue presence of some symptoms, 
such as, abdominal pain, lethargy and diarrhoea in patients following GFD 
(Dewar et al., 2012). This was also reported in other study with less 
percentage of individuals, 5-10%, and which also reported presence of 
persistent villous atrophy and continued CD symptoms (Häuser et al., 2010). 
Lack of adherence to GFD may be related to these findings. However, studies 
have shown that even a small quantity of daily gluten intake can cause 
changes in the small bowel mucosa biopsy. The exact quantity of gluten 
which CD individuals are allowed to consume and tolerate regularly, without 
any harmful effects still was not determined (Akobeng and Thomas, 2008). 
This Disagreement surrounding the classification of a GFD is due to lack of 
techniques for identifying gluten, as well as, lack of consistent scientific 
findings to determine the threshold of minimal gluten intake, which do not 
bring negative effects in the intestinal mucosa. GFD management depends on 
incessant collaboration, commitment and awareness of the patients, families 
and specialists, mainly, dieticians (Hill et al., 2005; Comino et al., 2012). 
2.3. Dietary adequacy and celiac disease  
CD is directly related to malnutrition around world, which is consequential of 
malabsorption. Earlier evidence has reported that over than 20% of CD 
individuals suffer from some nutritional deficiencies, which range from severe 
to mild deficiencies. These include deficiency of energy and protein, as well 
as, fibre and micronutrients deficiencies (vitamins and minerals) (Goyens et 
al., 1985; Wierdsma et al., 2013). Other common complication that is 
secondary to nutrition is lactose intolerance. This happens by low production 
of lactose caused by damage to the villi (Niewinski et al., 2008). Furthermore, 
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amongst the nutrients deficiencies, folate, iron and calcium is commonly 
related among CD patients, since the absorption of these nutrients occurs in 
the proximal small bowel (Saturni et al., 2010). Iron deficiency has been 
reported in 12% to 69% of CD Individuals (Halfdanarson et al., 2007).  Vitamin 
B12 deficiency has been shown to be significantly lower in untreated CD 
patients due to a reduction in area of absorption caused by villous atrophy 
(Halter et al., 2002).  Malabsortion of calcium, phosphorus and vitamin D are 
caused by pathology and mechanism of the disease (Rujner et al., 2004). 
Although, there is no many evidence related to the effects of macronutrients 
malnutrition in adults, studies has been demonstrated that in children can 
occur growth delay (Haines et al., 2008, Mearin et al., 2005). These nutritional 
deficiencies can cause secondary complications (West, 2004). For instance, 
iron may cause anaemia, fatigue and cognitive damage (Harper et al., 2007). 
Folate may also be involved in cases of anaemia and related to high level of 
homocysteine, which may result in thrombosis, osteoporosis and recurrent 
abortion (Haines et al., 2008; Yazynina et al., 2008; Bergamaschi et al., 
2008). Similarly, calcium and vitamin D are also linked to osteomalacia and 
osteoporosis (Rujner et al., 2004). Vitamin E deficiency has been associated 
to neurological disease and selenium to thyroid function in untreated patients 
with CD. Therefore, the severity of nutritional disorders depends on the 
degree of malabsorption and intestinal mucosal damage, and as well as, the 
period of time that the disease remained active and without being diagnosed 
(Haines et al., 2008). Studies have shown that many of these nutritional 
deficiencies can be treated followed by a strict GFD. For instance, studies 
have shown that after introduction of GFD there was an increase in calcium 
absorption in patients with CD (Capriles et al., 2009). GFD was also shown to 
improve iron deficiency, consequently, restoring growth problems in CD 
children (See and Murray, 2006). However, others have reported that GFD is 
not a guarantee of an appropriate nutritional intake, and that some of these 
deficiencies appear after therapy with GFD for more than 7 years (Saturni et 
al., 2010). Additionally, studies that examined dietary history of adults with CD 
reported that their diet is nutritionally adequate only the early years of 
treatment (Hallert et al., 2002). Other researches have explored the nutritional 
composition of processed GFPs and they showed that the level of lipids, 
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carbohydrate and salt are high in patients with CD (Saturni et al., 2010). In a 
similar study, was also shown an increase in fat and protein intake, and as 
well as, a decrease in fibre and minerals intakes, such as, iron and calcium 
(Hopman et al., 2006). Therefore, malabsorption effects can be severe in 
untreated or undiagnosed individuals and mainly in patients with a previous 
poor nutritional status (Rajpoot and Makharia, 2013). 
2.4. Gluten free products (GFPs) 
Gluten is the most important protein of structure formation in flour, and thus it 
plays an important role in baked products. Since, gluten gives the elastic 
appearances to the dough, as well as, is responsible for the crumb structure 
improvement and for the features of several baked products. Gluten 
withdrawal means a big problem and challenge for the bakers (Gallagher et 
al., 2004; Rajpoot and Makharia, 2013). Developing gluten free products with 
both great quality and nutritional value for the CD patients remains a major 
concern for the food industry. Many GFPs offered by the market still have 
some quality problems including poor sensory quality and shelf life compared 
with wheat products (Phimolsiripol et al., 2012; Laureati et al., 2012). For 
instance, typical gluten free bread seems to be denser when compared to 
typical non-gluten free bread (Haner, 2005). In most cases, the introduction of 
GFD causes confusion and concerns, regarding to gluten free foods that are 
allowed and included or which are not. Gluten free foods are distinguished in 
two types: foods naturally free of gluten and food produced without gluten by 
a purification process (Penagini et al., 2013). Naturally GFPs includes fruits 
and vegetables (frozen, canned or fresh); vegetable oils, beans, corn, rice, 
seeds, some different grains and pseudo-cereals (amaranth, quinoa, 
Buckwheat), fish, meats, eggs and dairy products. In the UK, it is perhaps 
allowed the use of wheat starch, which was extracted the gluten (Yazynina et 
al., 2008). Processed gluten-containing food not included in GFD are breads, 
pasta, pizzas, cereals, snacks, biscuits, sauces, soups, marinades, 
seasonings, soy sauce, some desserts, packaged flavoured rice, and 
processed cheeses (Niewinski et al., 2008; Penagini et al., 2013). 
Furthermore, it is also included medications that contain gluten (Gallagher et 
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al., 2004). Gluten free food is an economic burden for CD individuals, despite 
little study addressing this topic. However, it has been demonstrated that the 
food cost for patients with CD is clearly greater than is for general population 
(Long et al., 2010; Whitaker et al., 2009). Furthermore, CD women require 
more health care compared to non-CD women (Norström et al., 2012). 
Although, GFPs require greater expense compared to those containing 
gluten, it seems recently eating GFPs has become less complicated by the 
increase of the GPs available to be purchased by mail, in supermarkets or in 
pharmacies (Kinsey et al., 2008). In addition, patients can buy a variety of 
gluten free products, including flours and baking mixes, and also many gluten 
free cookbooks have been very useful providing a number of recipes and 
advices for gluten free costumers. This availability provides a greater food 
choice for CD patients and an increase in the variety of the diet, which 
enables patients feel normal when they are with relatives (Niewinski et al., 
2008). However, a complete elimination of gluten cannot be achieved, if not 
impossible, since gluten contamination can occur in GFPs, which makes very 
difficult to avoid gluten totally (Akobeng and Thomas, 2008). Cross 
contamination can occur from the harvest to storage, and as well as during 
transport and manufacturing. For example, oats that despite being considered 
a food without gluten, oat marketed may suffer contamination with grains 
containing gluten and this can also occur with other products free of gluten 
(Thompson et al., 2003). Thompson et al., (2010) in their study with 22 types 
of grains, seeds and flours considered inherently gluten free and that were not 
labelled as gluten free, found that 32% of them could not be considered as 
gluten free product as the level of gluten content were over than 20ppm. It is 
crucial that CD patients ensure through food labels or food companies that 
consumed product are free from gluten (Niewinski et al., 2008). Despite small 
gluten content in GFPs, in which may be harmless for many patients, this can 
lead to serious effects on individual with CD (Collin et al., 2004; Catassi et al., 
2007). Authorities of the food regulating organization recommend that for a 
GFP be considered as free from gluten, the level of gluten content should be 
less than 20 mg/Kg, and denominated as very low gluten content whether the 
gluten content level is between 20 mg/Kg-100mg/Kg (Food Standards 
Agency, 2012). Therefore, GFPs must be clearly labelled and CD patients 
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have to be well informed or educated in order to interpret them without 
mistakes. This helps CD patients choose the best GFPs (Penagini et al., 
2013). 
2.5. Compliance with a gluten free diet  
Compliance with a gluten free diet can be assessed using laboratory, 
histological and clinical information, and dietary intake (Capristo et al., 2000; 
Cummins et al., 2011). Many patients consider adherence to GFD as a 
challenge and difficult to adhere to because GFD can be very restrictive, and 
also because a little amount of gluten can stimulate serious results on clinical 
and histological parameters (Mayer et al., 1991). Consequently the failure on 
following their dietary self-management has demonstrated to affects not only 
the physical but also the psychological of those patients (Rose and Howard, 
2014). The adherence to a GFD seems to vary from poor to satisfactory 
(Butterworth et al., 2004). In children, compliance with a GFD seems to be 
less affected, as their parents are the responsible for their feeding. In 
adolescents and adults, it is more complicate, since they tend to give up 
easily of their dietary management (Errichiello et al., 2010). Among elderly 
people, the introduction of GFD may not be well accepted, as it requires a 
new dietary practise, which they may find difficult to comply, as it is necessary 
to break olds habits. In some case, this non-compliance by this population is 
cause by little evidence of clinical improvement  (Vilppula et al., 2011). 
Compliance with a GFD requires a significant self-determination on the part of 
each individual with CD. A recent study shown that the compliance is 69.4% 
(Araujo and Araujo, 2010) and may range from 45 to 80% (Ciclitira et al., 
2005; Hill et al., 2005). The compliance among young people is of 52% to 
81% in Europe. This variation in compliance, seems to depend on their 
believes, importance or reasons related to GFD (Hopman et al., 2006). 
Importantly, compliance with a GFD has reported to be associated with the 
recovery of medical conditions, the improvement of nutritional status 
(Nachman et al., 2009; Capristo et al., 2000; Samasca et al., 2014), and as 
well as, with decreased of gastrointestinal malignancies (Vilppula et al., 2011), 
the decreased of symptoms and risk of complications (Sainsbury et al., 2013), 
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and a guarantee of a better quality of life (Bellini et al., 2011; Nachman et al., 
2010). Therefore, Following and maintaining a strict GFD is extremely 
important for CD population (Sainsbury et al., 2013; Lee and Newman, 2003). 
It is clear that a lack of compliance can be the major threat for the disease 
remission. Many factors have been related to non-compliance by the CD 
patients. This includes cost of GFPs and limited availability of gluten free 
alternatives (Vilppula et al., 2011; Hall et al., 2009), lack of labelling 
information and education on the part of patients, family and some stores 
workers (Biagi et al., 2009); confusion, embarrassment, stress and anxiety 
(Rose and Howard, 2014); and food contamination (Rajpoot and Makharia, 
2013). Thus, understand the factors that are related to a best adherence and 
obedience to GFD is required in order to improve the resources and develop 
new strategies to support CD patients  (Leffler et al., 2007). Considering that 
GFD is essential for the control of the CD and health of the patient, and that 
there are few related studies, it was decided to realize this study (Sainsbury et 
al., 2013; Leffler et al., 2008). 
2.6. AIMS 
This study aims to verify the level of compliance to a gluten free diet and the 
nutritional status of patients with coeliac disease. For this purpose, it was 
measured BMI, dietary intake, and applied a questionnaire related to GFD 
compliance to NHS celiac patients. 
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3. METHODS 
3.1. Design  
This study is a cross sectional study with qualitative and quantitative 
approach, since this study describes the characteristics of CD population, 
such as compliance, nutritional status and dietary intake, and thus shows the 
important aspects related to the objective of this research. 
3.2. Sample  
Participants of this study came from a PhD study, which is still in progress. It 
was contacted 1000 CD patients of different ethnicity profile, both gender and 
who are in database of Leicester General Hospital NHS Trust.  
Inclusion and exclusion criteria  
All participants were patients with coeliac disease aged over 18, were living in 
Leicestershire area and were following GFD for at least 3 months. It was also 
included patients who gave their consent and were able to fill the forms. 
3.3. Materials 
Demographic Measures 
From the hospital database was obtained demographic information 
including age, gender, ethnicity and CD diagnosis. 
Level of compliance  
Compliance with a GFD was measured according to Butterworth et al., 
(2004), and it was complemented using a short questionnaire obtained from a 
similar study by Leffler et al., (2009) (see Appendix 01). Where was evaluated 
adherence to GFD using a five point Liker scale, which varied from highly 
compliant to “not following a gluten free diet at this moment”. Patients who 
scored from 0 to 16 were considered as compliant and those scored from 17 
to 35 as non-compliant. Then a nutritionist who was expert in CD evaluated 
the patients for GFD adherence. 
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Three-day food diary 
All participants filled a short diary questionnaire of 3 pages with instructions 
explaining how to use and measure portion sizes (see Appendix 02). 
Diet plan 6 
It was used the nutrition analysis software package 6 in order to analyse the 
food diaries  (Shepherd and Gibson, 2013). The entire software data sources 
were used. However, in case of not existence of a GFP on the software, it 
was made a web search of the GFP referred by the participant, and after, all 
nutritional profile of the products were added on the software, wherefore, it 
was followed the ingredient and the nutrition information provided by the 
manufacturer.  For processed GFP reported, it was used the same brand for 
all those who reported have used the same type of product. For example, 
same type of gluten free white bread was used for all patients who reported 
intake of gluten free white bread. For fresh prepared meals or food, the 
nutritional profile was obtained based on the information of the ingredients 
given by the participants (Shepherd and Gibson, 2013). It was also defined 
which GFPs were most indicated by the non-compliant participants from the 
obtained result of analysis done.  
Nutrients  
To verify the adequate intake of macronutrients (carbohydrate, protein, fat), 
micronutrients (calcium, vitamins B6 and B12, total folate and iron) and fiber 
were used the dietary reference intakes (DRIs), such as, estimated average 
requirement (EAR) and adequate intake (AI). Total energy intake was 
determined according to estimated energy requirement (EER). Fiber energy 
density was evaluated according to recommended daily intake (RDI), and was 
classified as very low when energy density results were less than 0.6 Kcal/g; 
as Low when were between 0.6 to 1.5 Kcal/g; as medium when were between 
1.5 to 4 Kcal/g; and as High when the outcomes were more than 4 Kcal/g 
(Stookey, 2001; Department of health Report and Social Subjects, 1991). 
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Anthropometry   
Recent Weight and height were obtained through the hospital database.  
Body Mass Index (BMI) 
BMI was calculated using the following formula: weight (Kg) / height (m2) 
(Bardella et al., 2000). Next the BMI data were classified using the World 
Health Organization Criteria: BMI <18.5 kg / m2 (Underweight); BMI> 18.5 
and to 24.9kg / m2 (Eutrophic); BMI> 25 and up to 29.9kg / m2 (overweight) 
and BMI> 30,0 kg / m2 (Obese) (Flegal et al., 2010; Kabbani et al., 2012). 
3.4. Procedure  
The ethical approval of this study was given both by University of 
Roehampton and Leicester General Hospital NHS Trust and was obtained 
through my supervisor.  After that, this search started by analysing the 
database of the patients with CD in order to identify patients who are 
according to criteria for inclusion and exclusion pre-established. Then it was 
printed out the consent form, the questionnaire and the 3-day food diaries. 
After being read and explained about the aim and any doubts related to this 
study all participants gave their consent. 
The PhD student has stamped the questionnaires and the 3-day food diaries 
with a reference number of identification to preserve the anonymity of the 
patients, and then has sent them by post with a return envelope. The 
participants also received with the questionnaire a message written in seven 
different languages informing that in case of they do not understand English, 
the researcher are available to clarify any doubts in their native language. The 
3-day food diaries were sent with the use instruction and a guideline about 
how to measuring portion sizes. Demographic information and anthropometric 
measures were obtained by database of the hospital, and height and weight 
data were used to calculate the BMI. All data were collected between 2014 
and 2015. All diaries data were analysed using diet plan software 6.0 and 
then reduced in nutrients. It was also identified the GFPs most mentioned by 
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non-compliant patients from the analysis of food diaries (Shepherd and 
Gibson, 2013). Lastly, all data collected were transferred to an excel template 
and then analysed using a Computer Package for Social Sciences (SPSS) 
version 21 available in the Roehampton University IT helpdesk. 
3.5. Ethics  
University of Roehampton and the authority of NHS Health Research gave the 
ethical approval, and the reference and protocol number are 14/LO/2128 and 
CD/RU/01, respectively (Appendix 03). Participants gave their consent and 
were informed that they were free to withdraw from this study at any stage. To 
maintain their anonymity, each of them was identified with a reference 
number. 
3.6. Statistical Analysis  
SPSS version 21 was used for statistical analysis, and statistical significance 
was considered at p value 0.05. Populations of the study were determined 
using descriptive statistics of which includes means, standard deviations (SD), 
median, range, correlation coefficient, frequencies and percentages. For 
describing the population, data were divided in two groups of variables: 
categorical that included gender, ethnicity, GFD on prescription, length of 
symptoms before GFD, frequency of gluten containing food inclusion in 
patients′ diet, meeting RNI-intake of nutrients, symptoms after GFD and type 
of symptoms after GFD (nausea, vomiting, mouth ulcers, stomach pain, 
fatigue, others); and continuous variables that involved age, weight, height, 
BMI, level of compliance and nutrients intake (carbohydrate, protein, fat, fibre, 
vitamin B6 and B12, calcium, total folate, iron).  
Variables that were considered as independent were age, gender, ethnicity, 
weight, height, energy intake, nutrients intake (carbohydrate, protein, fat, fibre, 
vitamin B6 and B12, calcium, total folate, iron), GFD on prescription and 
source of gluten containing food, length of symptoms before GFD. As 
dependent were: BMI, meeting RNI-intake of nutrients, symptoms after GFD, 
type of symptoms after GFD (nausea, vomiting, mouth ulcers, stomach pain, 
!! ! 21!
fatigue, others), level of compliance and frequency of gluten containing food 
inclusion in patients′ diet. Normality of the distribution was defined using 
Kolmogorov-Smirnov statistic. 
For all differences analysis between compliant and non-compliant patients 
were used Mann-Whitney test and/or Chi-square test. The differences verified 
between these two groups were related to age, gender, ethnicity, weight, GFD 
on prescription and frequency of gluten containing food inclusion in patients′ 
diet. It was also identified differences in BMI, energy intake, type of symptoms 
after GFD (nausea, vomiting, mouth ulcers, stomach pain, fatigue, others), 
nutrients intake (carbohydrate, protein, fat, fibre, vitamin B6 and B12, calcium, 
total folate, iron) and meeting RNI-intake of nutrients. Correlation between 
BMI and energy intake, fat and fibre was done using Spearman′ and Pearson′ 
correlation tests. All tests were used in order to test and responding the 
hypotheses of this study: whether there are differences between compliant 
and non-compliant patients in nutritional intake, anthropometry and clinical 
presentation of the CD after following a strict GFD 
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4. RESULTS  
4.1. Descriptive 
By the time of data collection only 100 patients had sent the questionnaires 
and the food diaries but only 86 patients met all of both criteria for inclusion 
and exclusion. Thus, the participants constituted by 63 (73.3%) female and 23 
(26.7%) male, aged between 19 to 64 years old (mean 46 / SD 14.5), and 
95.3% were European, 1.2% were Muslim, 1.2% Sikh, 1.2% Hindu and 1.2% 
did not answer. The mean results of Weight and height were 74kg (SD 4) and 
1.65 m2 (SD 6), respectively. Overall, the mean BMI results were 27.5 kg/m2 
(SD 1.8). Table 01 shows a brief overview of results of age, gender, ethnicity, 
energy intake and BMI divided in two groups, compliant and non-compliant 
patients (Appendix 04). 
Table 01. Mean and (SD) of demographic information, energy intake and BMI 
of compliant and non-compliant patients (Appendix 05). 
 
COMPLIANCE GROUPS 
Compliant 
N= 71 
Non-compliant 
N=15 
Age (years) 47.2 (14.3)* Age (years) 42.9 (15.7)* 
Gender      (n)        
             Female 
            Male 
54 
Gender     (n)         
                  Female 
                   Male 
 
9 
 
17 
 
6 
Ethnicity   % 
(European) 
97.2 Ethnicity % 
(European) 
86.7 
Weight  74.6 (4.3)* Weight  73.9 (4.9)* 
Energy intake 
(Kcal/day) 
1400 (364.5) Energy intake 
(Kcal/day) 
1342 (422.6)* 
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4.2. Compliance with a gluten free diet  
Regarding to compliance with a GFD, according Leffler score, analyses 
demonstrated that the proportion of compliant patients (82.6%, 71 patients) 
was higher than non-compliant (17.4%, 15 patients). The mean Leffler score 
for compliance was 13.5 (SD 4) (Appendix 07). By analysing how often the 
patients include food-containing gluten on their diet, the results showed that 
most of reported answers were “never” by 69.8% and “once a month” by 
15.1% (Figure 01). Findings related to GFD on prescription showed that 
34.9% of patients answered did not receive, 62.8% that received and 2.3% 
answered the question as not applicable to them (Figure 02). 
 
Figure 01. Frequency of consumption of products containing gluten in the 
diets of the patients (Appendix 06) 
3.5!
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Figure 02.  Distribution percentage of GFD on prescription (Appendix 06) 
Table 02 shows the comparison between compliant and non-compliant in 
terms of age, gender, ethnicity, weight, GFD on prescription and frequency of 
consumption of products containing gluten in the diets. No significantly 
difference was found when was compared the two groups related to age 
(p=0.44) and weight (p=0.60). In both group the majority of the patients were 
female and European (compliant 76.1% female and 97.2% European; non-
compliant 60.0% female and 86.7% European). There was a high difference 
related to percentage of students who reported have received GFD on 
prescription between compliant (33.8%) and non-compliant (40.0%). 
Regarding to frequency of consumption of products containing gluten on diet, 
73.2 of compliant answered never included compared to 53.3% of non-
compliant. The group of food that contain gluten in their composition eaten in 
transgression were bread, cereal, cake, pizza, biscuits, porridges, pasta, fish 
fingers, sausages and gravy. 
34.9!
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Table 02. Values of difference in age, gender, ethnicity, weight, GFD on 
prescription and frequency of consumption of products containing gluten on 
diet between compliance groups (Appendix 07) 
 Compliance groups 
Variables Compliant 
N=71 
Non-compliant 
N=15 
P 
Age (years)* 51 (45)** 42 (43)** 0.44 
Gender (%) ***    
Female   76.1 60.0  
Male  23.9 40.0  
Ethnicity  (%) ***    
European  97.2 86.7  
Muslin --- 6.7  
Sikh --- 6.7  
Hindu --- ---  
No answer 1.4 ---  
Weight (Kg)* 73.7 (16.7)** 72.7 (17)** 0.60 
GFD on prescription  (%)***  
                                      Yes  63.4 60.0  
No  33.8 40.0  
Not applicable  2.8 ---  
Frequency of consumption of 
products containing gluten on diet 
(%)*** 
 
No answer  4.2 ---  
Never  73.2 53.3  
Once a moth  12.7 26.7  
Once a week 2.8 6.7  
Daily (%) 4.2 13.3  
Other (%) 2.8 ---  
*Man Whitney statistic test; ** Median and (range);  *** Chi-square test 
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4.3. Dietary intake 
 On the Table 03 is represented the results of the dietary intake of the 
patients. Energy intake mean was of 1390 Kcal/day (SD 373.2), which is not 
according to EER. The mean of carbohydrate intake (168.8 g/day, SD 55.8) 
was above of EAR and mean fat intake (54.1 g/day, SD 18.1) was normal 
compared to AI recommendation. Protein mean intake was 51.3 g/day (SD 
13.4), which is under of EAR daily recommendation. The fibre intake and fibre 
energy density results are lower than recommended by AI and DRIs, 14.5 
g/day and 1.06 g/day, respectively. Amongst the micronutrients, the mean 
value of vitamin B6 (1.2 mg/day) calcium (492.2 mg/day), total Folate (157.8 
mg/day) and iron (6.0 mg/day) are below the recommended level by EAR and 
AI, unlike the mean value of the vitamin B12 is above (2.96 mg/day) 
(Appendix 08). 
Table 03. Results of macronutrients, fibre and micronutrients intake, and fibre 
of CD patients: Mean and recommendation of nutrients intake (RNI). 
Nutrients intake Mean (RNI, Department of 
health Report and Social 
Subjects, 1991) 
 
Std. 
Deviation 
Energy intake (Kcal/day) 1390.3 (1600-2000 Kcal/day) 373.3 
Protein (g/day) 51.3 (64 g/day or 0.8g/Kg) 13.3 
Fat (g/day) 54.1 (53 g to 65 g/d) 18.1 
Carbohydrate (g/day) 168.8 (130 g/day) 55.8 
Fibre (g/day) 14.5 (25 g to 30 g/day) 5.3 
Vitamin B6 mg/day) 1.2 (1.3 mg/day) 0.4 
Vitamin B12 mg/day) 2.96 (2 mg/day) 3 
Calcium mg/day) 492.2 (1000 mg/day) 257.6 
Iron mg/day) 6.0 (8 mg/day) 2.9 
Total folate (mg/day) 157.8 (320 mg/day) 76.9 
Fibre energy density (g/day) 1.06 (> 4 Kcal/g) 0.4 
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Figure 03 demonstrates a summary of the percentages of meeting RNI-intake 
of fibre, vitamin B6, Vitamin B12, calcium, Iron and total folate. The results 
show that 67.4% of the patients meet the recommendation intake of Vitamin 
B12 intake. However, the percentage of those that did not meet intakes is 
higher when it comes to other studied nutrients: fibre 95.3%, vitamin B6 
65.1%, calcium 96.5%, iron 83.7% and total folate 98.8% of patients. 
 
Figure 03. The percentages of meeting intake of fibre, vitamin B6 and B12, 
calcium, iron and total folate of the CD patients (Appendix 08) 
There was no significant difference in consumption of energy intake, 
macronutrients (energy intake p=0.470, carbohydrate p=0.785, protein 
p=0.163, fat p= 0.406) and fibre (fibre p=0.076) between compliant and non-
compliant patients. As well as, no significant difference was found amongst 
micronutrients between the two groups (vitamin B16 p=0.746, vitamin B12 
p=0.470, iron p=0.342, folate p= 0.524 and calcium p=0.082) (Table 04). 
Nevertheless, it was found a high difference between compliance groups 
related to energy density of the fibre (p=0.029). Table 05 shows the meeting 
RNI-intake of nutrients of compliant and non-compliant patients, as it is 
possible to see, 94.4% of compliant and 100% of non-compliant did not meet 
0!10!20!
30!40!50!
60!70!80!
90!100!
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the RNI-intake of fibre. Meeting RNI-intake of vitamin B6 was seen in 35.2% 
of compliant and 33.3% of non-compliant; meeting RNI-intake of vitamin B12 
in 66.2% of compliant and 73.3% of non-compliant, and meeting RNI-intake of 
iron in 14.1% of compliant and 26.7% of non-compliant.  Comparing meeting 
RNI-intake of calcium and folate between groups, 100% of non-compliant 
patients did not meet the RNI-intake for both micronutrients; and 95.9% of the 
compliant patients meet RNI-intake for calcium and 98.6% for folate. 
Table 04. Difference between compliance groups related to macronutrients, 
micronutrients, fibre and energy density of fibre: median, range and p value 
(Appendix 09). 
 
 
Nutrients                       
Compliance groups Difference 
between 
compliant and 
non-compliant 
Compliant Non-
compliant 
Median (range) P* 
Energy intake 
(Kcal/day) 
 1329 (1822) 1279 (1719) 0.470 
Carbohydrate (g/day) 159.3 (313) 159.7 (163.3) 0.785 
Protein (g/day) 50.4 (80.4) 43.2 (41.0) 0.163 
Fat (g/day) 51.2 (92.9) 58.8 (60.8) 0.406 
Fibre (g/day) 14 (26.4) 12.5 (15.7) 0.076 
Vitamin B6 (mg/day) 1.1 (2.1) 1.1 (1.3) 0.746 
Vitamin B12 (mg/day) 2.5 (26.1) 3.3 (5.2) 0.470 
Calcium (mg/day) 467 (1900) 378 (553) 0.086 
Iron (mg/day) 5.5 (14.0) 6.0 (8.4) 0.342 
Total folate mg/day) 155 (442) 142 (196) 0.524 
Fibre Energy density 
(g) 
1.0 (1.86) 0.86 (0.87) 0.029 
* Man Whitney statistic test 
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Table 05. Difference between compliant and non-compliant patients related to 
meeting RNI-intake of fibre and micronutrients (Appendix 10). 
 
 
 
Meeting RNI-intake of 
nutrients  
Compliance groups 
Compliant Non-compliant 
N (%) 
Fibre (g/day)*   
Yes 4 (5.6) --- 
No  67 (94.4) 15 (100) 
Vitamin B6 (mg/day)**  
Yes  25 (35.2) 5 (33.3) 
No  46 (64.8) 10 (66.7) 
Vitamin B12 (mg/day)**  
Yes  47 (66.2) 11 (73.3) 
No  24 (33.8) 4 (26.7) 
Calcium (mg/day)**  
Yes  3 (4.2) --- 
No 68 (95.8) 15 (100) 
Iron (mg/day)**  
Yes  10 (14.1) 4 (26.7) 
No  61 (85.9) 11 (73.3) 
Total folate mg/day)**  
Yes  1 (1.4) --- 
No  70 (98.6) 100 
* Chi-square test  
4.4. Nutrition status of the patients  
Correlation between BMI and energy intake of patients revealed that although 
the correlation coefficient (0.304) indicates that the relationship between these 
two variables is weak, the values of P says that correlation is significant  
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(p=0.004). A weak but significant correlation between BMI and fat and fibre 
were also found, p= 0.026 and p=0.041, respectively (Table 06). Figure 04 
shows that the BMI increase relatively with the increase of energy intake. The 
BMI mean of compliant patients were 27.7 (SD 1.8) and non-compliant 
patients was 26.6 (SD 1.7). The BMI between the groups was highly different 
(p=0.048) (Table 07). 
Table 06. Correlation between BMI and fat, fibre and energy intake  
(Appendix 11) 
 Correlation 
 P (r) 
BMI and energy intake 0.004 (0.304)** 
BMI and fat 0.026 (0.241)* 
BMI and fibre 0.041 (0.220)* 
*Spearman’s! correlation test 
*Pearsons! correlation test 
 
Figure 04. Result of correlations between BMI and energy intake  
(Appendix 11) 
P =0.004 
R =0.304 
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Table 07. BMI mean and SD of compliant and non-compliant patients, and the 
difference in BMI between the two groups (Appendix 11) 
 
Nutritional 
parameter  
Compliance group Difference between 
the groups Compliant Non-compliant 
Mean (SD) P* 
BMI (Kg/m2) 27.7 (1.8) 26.6 (1.7) 0.048 
* Man Whitney statistic test 
4.5. Symptoms before and after GFD adherence 
Regarding to length of symptoms before adherence to GFD, 36% of the 
patients reported symptoms for “more than 3 years “, 29.1% for “1 year to 3 
years”, 18.6% for "6 months to 1 year", 12.8% for “less than 6 months", 2.3% 
answered "other" 1.2% did no answer (Figure 05). The percentage of patients 
with symptoms after GFD treatment was of 82.6%. Percentage of those that 
reported no symptoms after GFD was of 7%, and  “not applicable” was stated 
by 10.5% (Figure 06).  
 
Figure 05. Length of symptoms before GFD (Appendix 12) 
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Figure 06.  Symptoms after introduction of GFD (Appendix 13) 
The types of symptoms reported by compliant and non-compliant patients are 
represented on Table 08. Fifty-two compliant patients reported nausea and 
Vomiting and mouth ulcers by 63 of them. High number of compliant (59 
patients) reported do not have symptoms as they do not eat food-containing 
food. Regarding to non-compliant, 11 of them reported fatigue, 9 nausea and 
vomiting, and diarrhea, and 13 of them said do not have symptoms. 
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Table 08. Types of symptoms mentioned by compliant and non-compliant 
patients (Appendix 13). 
  Compliance groups 
Symptoms *  Compliant  
 N=71 
Non-compliant 
N=15 
Nausea and vomiting No  52 09 
Yes  19 06 
Diarrhea  No  36 09 
Yes  35 06 
Fatigue  No  39 11 
Yes  32 04 
Mouth ulcers No  63 13 
Yes  08 02 
Stomach pain No  36 06 
Yes  35 09 
Not applicable: do not 
eat gluten containing 
food and hence do not 
know 
No  59 13 
Yes  12 02 
Others No  50 11 
Yes  21 04 
* Chi-square test 
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5. DISCUSSION 
5.1. Compliance with gluten free diet  
It is highly recognized that treatment for celiac disease is based exclusively on 
GFD, which have to be strict and for a lifetime (Castillo et al., 2014). 
Individuals with CD may find that GFD is an overwhelming responsibility and 
extremely burdensome for them (Hopper et al., 2007). Therefore, compliance 
with a GDF has been considered a major challenge, even more recently due 
to increasing growth of diagnosis (Errichiello et al., 2010). Monitoring whether 
the CD patients are complying with GFD is certainly an important aspect of 
long-term CD management (Green et al., 2015; Biagi et al., 2009). 
In this research, compliance with a GFD was extremely higher (82.6%), as 
well as, non-compliant group (17%) was much high compared to others 
published studies. Sainsbury et al., (2013) in a recent study using the same 
Leffler′s questionnaire to assess adherence to GFD with 390 CD adults’ 
participants found that 52.7% of them reported excellent adherence to GFD, 
37.2% moderate adherence and 6.2% fair to poor adherence. Similarly, 
Rubio-Tapia et al., (2010) assessed compliance to GFD, using dietician 
interview with 241 patients and showed that 66% of those assessed had good 
compliance, 21% moderate and a poor compliance was found in only 13% of 
them. Leffler et al., (2007) demonstrated in their study with adults CD only the 
rates of excellent and good adherence to the GFD, which were 44.2% and 
34.4%, respectively. A high adherence rate to GFD was also shown in other 
prospective studies. For example, a prospective study with 490 participants 
compared three study groups in terms of self-rated adherence to GFD. The 
rates of adherence were elevated in the three groups: patients with classic 
symptoms had 85% of adherence, those with extra-intestinal symptoms 78% 
and the screen-detected group had 91% of adherence (Ukkola et al., 2011). 
Viljamaa et al., (2005) verified dietary compliance in 53 screen-detected 
patients with 14 years of followed-up and in 44 symptom-detected patients 
with 10 years of followed-up, through an interview made by an experienced 
dietician. The study found that 83% of screen-detected patients has followed 
a strict GFD and 14 % a fairly strict GFD, and in the same way, 77% of 
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symptom-detected participants kept a strict GFD and 16% a fairly strict 
adherence.  Despite many studies has been shown good rate of compliance, 
it is noticeable that the choice of methods used to measure adherence to GFD 
may influence negatively the results by overestimating their adherence, for 
example, self-reported method, which may not be completely reliable, since 
the patients may report an inaccurate self-assessment (Biagi et al., 2009). On 
the other hand, Sainsbury and Mullan (2011), who measured behavioural 
beliefs related to GFD adherence in CD individuals demonstrated that there is 
a significant relationship between intention to maintain a strict GFD and 
adherence to GFD. They suggested that many patients believe that the 
advantages of a strict gluten-free diet are the main reasons that lead them to 
maintain the diet compared to the disadvantages. Furthermore, they showed 
that poor GFD adherence is related to increased concern of the patients in 
avoiding any inconvenience or offences that they might cause to others. 
Poorer adherences, as well as, lower intention were associated with belief 
that it is easy to have a balanced gluten free diet. Due to these findings the 
authors reported that is necessary to monitoring the diet of the patients to 
prevent possible exposure to gluten. 
Factors related to compliance with a GFD were not methodically analyzed in 
this study. However, voluntary dietary transgression was identified in a 
representative number of patients who reported to include food-containing 
gluten on their diet, and this occurred more among non-compliant patients 
(22.5% of compliant, 46.7 of non-compliant). Our findings are consistent with 
Shepherd and Gibson, 2013. In their study were compared 55 patients who 
were on a GFD over than 2 years to 50 newly diagnosed. Overall, was found 
that 75% of patients were following strictly a GFD, in which 10% of those 
patients reported inclusion of gluten containing food unconsciously and 23% 
reported to consume gluten occasionally. In a 5 years-study was determined 
adherence to GFD and was evaluated its strictness.  Food frequency 
questionnaire was used as method interview in 95 adults with CD, and 
patients were divided in 3 groups: group A no detected transgression, group B 
moderate transgression and group C large transgression. This research found 
no transgression in 40 compliant patients (group A) and transgressions in 55 
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non-compliant patients (group B and C). Among non-compliant, 38 patients 
identified the transgression as intended and 17 as unintentional. Patients 
reported some reasons for voluntary transgression, such as, absent of 
symptoms after ingestion of GFPs, GFPS are less tastiness than habitual 
food, GFPs are more expensive, cultural reasons, and GFD brings more 
restrictions than benefits. Unintentional transgression were justified by 
pharmaceuticals that (Vahedi et al., 2003). Errichiello et al., (2010) found 
dietary lapses among CD patients in a study with adolescent and young 
adults patients. Among 204 patients, 73.5% of them did not committed dietary 
transgression but 26.5%, which is similar to our study, admitted frequent or 
occasional dietary transgression. A Brazilian study with 105 CD patients, in 
which 90.4% were on GFD also found that significant percentage of their 
participants (67.1%) consumed gluten containing food involuntarily or due to 
lack of food options/ or food information available in public space (Araujo and 
Araujo, 2011). Types of food containing gluten consumed in transgression 
were mostly processed food, and this was also mentioned in a prospective 
study of Errichiello et al. (2010). Their outcomes shown that snack, including 
sweets, and bread were the sources of food containing gluten most reported 
in transgression by 38.9% of 54 patients. These findings are consistent with 
Araujo and Araujo, (2011) and Leffler et al. (2008), who mentioned a number 
of factors that were related to consumption of these food containing gluten, 
such as, limited alternatives at food shops, alternatives foods require extra 
spare time and energy to be prepared, lack of food manipulation and culinary 
skills, limited financial resource and difficulty of finding adequate menu for the 
family, and difficulty to vary the diet. 
There are few consistent studies that examined difference related to 
demographic information between compliant and non-compliant participants  
(Errichiello et al., 2010; Hall et al., 2009). In this present study, higher number 
of patients were female in both groups but percentage of compliant female 
patients (76.1%) were bigger than non-compliant (60%), and non-compliant 
male patients (40%) were higher than male compliant (33.8%).  Regarding to 
ethnicity, 97.2% of compliant were European compared to 86.7 of non-
compliant (p=0.031). Errichiello et al., (2010), for example, did not find any 
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difference between genders or among age groups related to compliance with 
GFD. Kratzer et al., (2013) verified CD prevalence in 2157 German 
participants. This prospective study revealed 52% of them were women and 
48% men. High prevalence of white and female (76.6%) patients with CD 
were reported in other prospective study, where was compared five methods 
of measuring adherence to GFD in adults patients aged over 18 years old. 
This study also showed that all patients treated at the Medical centre selected 
for that study were female and white (71.7%). Additionally, an expert 
nutritionist reported that female demonstrated lightly better GFD adherence 
(Leffler et al., 2007). Butterworth et al. (2005), compared factors that are 
related to compliance with a GFD between white Caucasian (n=66) and South 
Asian (n=21) CD patients. They found that large percentage of white 
Caucasian (74%) was on a strict or moderately strict GFD compared to South 
Asian (66.6%). Results of another study carried out by Kabbani et al., (2012) 
demonstrated that good and poor adherence was mostly amongst white 
populations and females. Good adherence was described in 77% of female 
participants and in 94% of white populations, and the mean age was 52.2 
years old. Poor compliance was reported in 72% of female and in 97% of 
white populations and the mean age was 53 years old. Therefore, as various 
studies with CD patients have demonstrated majority of CD patients are white, 
female and with European ancestry (Casellas et al., 2006; Ludvigsson et al., 
2014; Perreira et al., 2006).   
Despite this study did not find difference in the answers related to GFD on 
prescription between groups, this study verified that the percentage of non-
compliant patients (40.0%) who reported not be given GFD on prescription 
was higher than the compliant patients (33.8%). In a recent study Tennyson et 
al. (2013) measured the interest level of 465 patients related to the use of 
medication in the treatment of CD using a Coeliac Dietary Adherence test. 
When patients were asked how often a dietician saw them, only 5% answered 
regularly compared to 20% of those who answered have never been seen by 
a dietician. Moreover, in another recent study, 7% of 113 patients reported did 
not receive any follow-up for CD. Authors also found that 35% of them were 
considered to have a consistent follow-up, which was according to American 
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Gastroenterology Association, and 58% had an inadequate follow-up for CD. 
Furthermore, they suggested that a practise of inadequate monitoring tends to 
affect negatively the long-term positive effects of GFD compliance (Herman et 
al., 2012). Nevertheless, Some doctors do not understand the importance of a 
strict and lifelong GFD, and consequently they might not prescribe GFP to 
their patients. All patients should be advised regularly, from the first 
consultation on the importance of adhering and maintaining a GFD for 
lifetime. Since, it is suggested that compliance with GFD can be improved 
through an adequate follow-up (Butterworth et al., 2004).  
5.2. Dietary intake 
A few studies have investigated the nutritional status of CD patients, the GFD 
nutritional quality and the influence of non-compliance, mainly, using dietary 
questionnaire (Kinsey et al., 2008). Dietary inadequacies is a common 
condition in CD and the nutrients most mentioned by many studies are iron, 
vitamin B12, calcium, folate, fibre, energy intake and macronutrients (Moreno 
et al., 2014; García-Manzanares and Lucendo, 2011). Therefore, It has 
demonstrated that it is extremely important for the health professionals, which 
work with nutrition education of patients with CD, to know whether gluten free 
diet is sufficient for CD individuals in order to meet its dietary or nutritional 
recommendations, as well as, to know the impacts of nutritional inadequacies 
on CD individuals health (Shepherd and Gibson, 2013). Findings of this study 
demonstrated that patients had low intake of protein, fibre, energy density of 
fibre, and todal energy intake, compared with the DIRs. However, it was found 
a higher intake of energy as carbohydrate, and the mean fat intake was 
according to the recommendation. Concerning to studied micronutrients, 
Vitamin B12 was the only above the nutritional recommendation. No 
significant difference was found in all macronutrients, micronutrients, and fibre 
intake between compliant and compliant, except fibre energy density. Meeting 
intake of nutrients were also analysed in our study. The percentage of 
patients who failed to meet RNI-intake of fibre, vitamin B6, calcium, iron and 
total folate were significantly above of those that meet the recommendation 
intake. Regarding to vitamin B12 the percentage of patients who meet the 
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RNI-intake was higher. All non-compliant patients did not meet RN-intake of 
calcium, folate and fibre. Additionally, percentage of non-compliant patients 
who did not meet RNI-intake of all micronutrient studied were higher then 
compliant patients, except for vitamin B12 that was higher amongst non-
compliant. 
Comparably, Ghen et al. (2001) showed the overall nutrient intake of 49 
patients aged between 45 to 64 years, on a GFD for 10 years. The mean daily 
intake of vitamin B6 (female 1.7 g/d, male 1.9 g/d), vitamin B12 (female 4.3 
g/d, male 5.3 g/d), Calcium (female 837 g/d, male 999 g/d) and carbohydrates 
(female 220 g/d, male 254 g/d) were considered high in both gender. Total 
Energy intake (female 220 g/d, 254 g/d) was according to Nordic Nutrition 
Recommendations (NNR). Folate (female 186 g/d, 172 g/d) and fibre (11.5 
g/d, 10 g/d) were lower than the recommendation. Hallert et al. (2002) carried 
out a study with 30 adults with CD, on a GFD for 10 years. They aimed to 
verify the prevalence of vitamins and mineral deficiency amongst those 
patients. Patients had a low mean daily folate intake (184 mg/d) and higher 
intake of vitamin B6 (1.8 mg/d) and vitamin B12 (5.1 mg/d). All values were 
compared to NNR. Moreover, they also correlated vitamin intakes with plasma 
levels but the correlations were weak (r < 0.18). Bardella et al. (2000) found 
high total energy intake amongst male (2314 Kcal/d) and normal amongst 
female (1609 Kcal/d). This study also indicated high consumption of fat and 
low of carbohydrates. Most recent study related to nutritional inadequacies in 
CD patients found that patients who were on GFD for 2 years had elevated 
intake of iron (male 15.8 mg/d, female 11.9 mg/d), calcium (male 909 mg/d, 
female 987) and total fat (67.9 g/d, 72.7 g/d), compared to AI and EAR. 
Energy intake (male female 2697 Kcal/d, 2040 Kcal/d), Carbohydrate (male 
294 g/d, female 236 g/d) and protein (male 98.8 g/d, female 89.2 g/d) also 
exceeded the recommendation. Total folate (male 403 mg/d, female 316 
mg/d) and fibre (male 30 g/d, female 22 g/d) were high only amongst male. 
Furthermore, fat and protein reached the recommendation for female (68.3 
g/d and 62.5 g/d) but were exceeded for male (92.1 g/d and 81.4 g/d). It were 
also demonstrated the number of patients with CD who did not reach levels of 
recommendations of some nutrients. Forty-nine patients failed to meet the 
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recommendations of fibre, 16 of vitamin B6, 48 of folate and 19 of calcium. 
Similarly another prospective study analysed the nutritional state as well as 
the nutritional management of GFD in CD patients aged 12-25 years old. All 
patients were found to have significantly lower intake of iron and fibre 
compared to Dutch and American recommendations. Patients older than 19 
years reached the American recommendation for calcium. Vitamin B6 values 
were above the Dutch recommendation. Additionally, 64% of them reported 
make use of GFPs fortified with vitamins and minerals and 47% stated using 
supplementation of those nutrients (Hopman et al., 2006). Despite studies 
have shown continues malnutrition amongst patients with CD even after using 
fortified GFPs and supplementation, it has been proposed that 
supplementation can be used for purposes of increasing the nutritional 
content in many gluten free products (GFPs) and as well as to increase 
nutritional intake in patients with the coeliac disease (Korus et al., 2009; 
Hallert et al., 2009; Penagini et al., 2013; Reilly et al., 2012). Another 
suggestion would be a new dietary approach as dietary modification, which 
includes new variants of wheat and detoxification of gluten (Rashtak and 
Murray, 2012). 
Although there is no published research addressing in detail about factors 
associated to nutrients inadequacy in individuals with CD even after GFD, few 
studies suggested some causes (Bardella et al., 2000; Moreno et al., 2014; 
Comino et al., 2012; Rubio-Tapia et al., 2010). It has been suggested that 
most of CD patients do not react positively to a GFD and possibly continues to 
have villous atrophy and then persistent malabsorption (Comino et al., 2012; 
Rubio-Tapia et al., 2010). Lanzini et al. (2009) found that despite adherence 
to GFD, it is extremely rare to find complete recovery of the duodenal 
impairment in adults with CD. Once the authors reported that after 
approximately 1 year and 3 months, only 8% of 465 patients had total 
histological duodenal recovery, 65% obtained remission and 26% remained 
the same. These findings discredit the possible benefits of GFD that have 
been highlighted by many studies for example, correction of nutritional loss or 
malnutrition (Haines et al., 2008). However, it has been also shown that poor 
compliance or non-compliance to GFD may influence the dietary intake of CD 
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patients (Kinsey et al., 2008). Voluntary consumption of foods containing 
gluten may be the reason for persistent injuries of the intestinal mucosa found 
in a perspective study with 236 participants with CD. This study showed that 
while 89 of them obtained recovery in the intestinal mucosa, 147 continued to 
have persistent injury, when was assessed the first follow-up biopsy. It was 
also demonstrated that amongst those patients with mucosal recovery, 75% 
was with good compliance, 20% was with moderate compliance and 4% with 
poor compliance to GFD. On the other hand, high level of non-compliance 
was found amongst those with persistent injuries of the intestinal mucosa.  
Good compliance was 61%, moderate 21% and poor compliance 18% 
(p=0.003) (Rubio-Tapia et al., 2010). Araujo and Araujo (2011) also evaluated 
adequacy of nutrients intake after introduction of a strict GFD. Thus, It was 
correlated gluten-free dietary tracking with nutrients and energy 
recommended for a good health, and a significant association was found as 
p=0.0315. The study concluded that patients who tried to not consume gluten-
containing food obtained a proper amount of nutrient and calories in their diet. 
Dietary inadequacy was also related to poor quality of GFD recommend 
currently, which do not provide adequate nutrients (Mearin et al., 2005). 
Since, when it is introduced GFD in patients′ lives occurs the elimination of 
some important foods that are rich in calcium, thiamine, niacin, protein, 
carbohydrates and energy, and it is also known that great part of processed 
foods have gluten and also need to be eliminated. All this can have a huge 
influence on nutritional contents of foods as was reported for many studies, 
and mainly, when there is no a good alternative for these products (Kinsey et 
al., 2008; Moreno et al., 2014). Thus, rigorous follow up and nutritional 
education, which includes food choice and composition, is important for 
prevention of malnutrition (Bardella et al., 2000). 
Although, various studies have shown persistent deficiency of nutrients after 
introduction of GFD (Grehn et al., 2001; Hallert et al., 2002), a prospective 
study has demonstrated a good clinical response to GFD in context of 
nutritional inadequacy (Caprisco et al. 2000). Interestedly, in a later study with 
39 adults CD, Caprisco et al. (2000) compared macronutrient and 
micronutrients intake between treated and untreated CD patients. It was found 
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that energy intake and carbohydrate did not vary significantly between groups, 
as energy intake and carbohydrate of treated were 8400 kJ/d and 4500 kJ/d, 
and untreated were 8300 kJ/d and 4600 kJ/d. However, the results showed 
that treated patients had an elevated intake of fat (2300 kJ/d) than untreated 
(2150 kJ/d), and protein intake was equal (1500 kJ/d).  Micronutrients 
amongst treated CD were also higher than untreated: iron 12.6 moll/L and 7.6 
moll/L, vitamin B12 311 mmol/L and 294 mmol/L and folic acid 17 mmol/L and 
11.8 mmol/L, respectively. It was also possible to verify that treaded patients 
had higher consumption of protein (89.5 g/d of protein) and carbohydrates 
(268.8 g/d of carbohydrates) and normal intake of fat (61g/d of fat) and total 
energy intake (2006 Kcal/d), when compared with the DRIs. Micronutrients 
were all according to the biochemical references values. However, it is 
important to emphasize that micronutrients were assessed using laboratory 
index, which comparing to dietary intake questionnaires, are more accurate 
regarding to the outcomes (Subar et al., 2003). Even though it was used in 
this present research the same methodology (3-day food diary) as other 
studies, underreported were noticeable, may suggest that during this study 
occurred alterations in usual food patterns of the participants (Hallett et al., 
2002). 
5.3. Nutrition status of the patients 
Recently, alterations in the CD clinical presentation have been indicated by 
various studies, which is now characterised by increasing overweight or 
obese prevalence amongst individuals with CD (Rybak et al., 2014). Likewise, 
this trend was observed in the present research, as both compliant and non-
compliant CD patients were found overweight. In addition, BMI of compliant 
patients was significantly higher than non-compliant (p=0.048). As this study, 
many other are concerned about the nutritional status of patients with CD. 
Tucker et al. (2012) in a study analysed 240 CD adults who attended a 
Dietetics institution for 10 years (1999 to 2009). The study demonstrated 
normal BMI in 53% of them and underweight in 3% but there was a significant 
percentage of overweight (44%). The Increase in overweight or obese 
occurred along with the increase in the numbers of patients, as while in 2002 
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were only 4 patients (25% of obese), at the time of study (2009) the number 
has increased to 52 patients (73% of obese). Dickey and Kearney, 2006 
verified BMI in 188 compliant CD patients who were on a GFD for 2 year. The 
BMI mean was 25.9, and with introduction of GFD 81% of those patients 
gained weight but 28% lost and 4% remained with same BMI. Gains of further 
weight were reported in patients who were initially overweight. Therefore, the 
number of overweight increased from 67 patients to 95, and also had an 
increase of obese patients, as 11 overweight patients and 2 who were in the 
normal BMI became obese. However, despite increasing overweight and 
obese, all studies that addressed the BMI of celiac patients have shown 
improvement in Body weight of these patients, while on GFD (Pulido et al., 
2013; Nachman et al., 2010). Additionally, case of stable BMI in CD patients 
was also reported in celiac patients, after specialized follow-up or good 
management of GFD (Ukkola et al., 2012; Bardella et al., 2000; Reilly et al., 
2012; Kabbani et al., 2012). Nachman et al. (2010), made a comparison 
between BMI of patients at 1 year of follow-up and 4 year of follow-up. Results 
showed a significant improvement in BMI of patients at 12 months of follow-up 
(p<0.0002), which maintained constant at 4 years of follow-up. A prospective 
cohort that was published in 2012 by Ukkola et al. assessed the influence of 
GFD on BMI, after 12 months of GFD introduction. Before GFD, 4% of 689 
were classified as underweight, 57% of as normal, 28% as overweight and 
11% as obese. After GFD, while underweight patients (69%) increased their 
body weight, those with overweight (18%) and obese (42%) had a decrease in 
weight. This positive effect of GFD on patients BMI was reported in both 
screen-detected and symptom-detected patients. However, despite it was 
seen positive changes in BMI, it seems that those changes were not related to 
dietary counselling given by heath professionals but with self-reported 
experiences on GFD and age at the diagnosis (young). Shepherd and Gibson, 
(2013) found an increase of mean BMI in newly diagnosed patients after 1 
year on GFD. Female increased from 22.9 kg/m2 to 24.4 kg/m2 and male from 
23.4 kg/m2 to 25.5 22.9 kg/m2, but male patients became slightly overweight. 
Experienced patients (2 years on GFD) were found with normal BMI. The 
mean BMI was of 24.2 kg/m2 and 25.0 kg/m2 for female and male, 
respectively. However, The two groups of patients did not differ significantly in 
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BMI. Similarly, this normal BMI were demonstrated in Bardella et al. (2000) 
study. They found only 7 patients with overweight, 12% were female and 10% 
were male. The mean BMI was 20.9 kg/m2 for female and 21.9 for kg/m2. 
Mild malnutrition, consequently low BMI has been demonstrated to be very 
common along with a poor mucosal recovery (Pulido et al., 2013). Kabbani et 
al. (2012) also presented in their study with 679 patients changes in BMI post-
diagnosis of CD. Normal BMI was verified in 65% of participants who were 
initially classified as underweight at diagnosis, and overweight or obese in 
4.4%. A significant percentage remained underweight (30.4%). Majority of the 
patients (80.0%) with normal BMI at the diagnosis remained the same and a 
small group became overweight or obese (17.0%). By comparing those who 
increased (21.2%) their body weight to those who decrease (4.8%), they 
found a significant difference (p=0.0001). Amongst those who were 
overweight before treatment:  17.3%remained obese, 18.7% normal weight 
and a majority remained overweight (64%). Interestedly, they reported that 
patients who had good adherence and those with poor adherence to GFD did 
not differ in BMI. It is clear the existence of conflicting results between studies 
concerning to the protective effect of GFD (Norström et al., 2012). However, 
despite these conflicting results between studies analysed, it is important to 
note that overweight or obesity are considered one of the most important risk 
factors to diseases related to the heart (Rybak et al., 2014; Kabbani et al., 
2012).  Results a study demonstrated that patients who were on a GFD for 1 
to 5 years had a significant increase in BMI (21.4 kg/m2 to 22.5 kg/m2; 
p<0.0001), as well as, total cholesterol (171.2 mg/dL to 181.4 mg/dL). On the 
other hand, a significant reduction in homocysteine (p=0.018) and 
triglycerides (p<0.0001). Thus proposing that patients diet were less probable 
to be artherogenic (Zanini et al., 2013). None of the above studies related BMI 
with quality of patients GFD. However, This present study found a significant 
correlation between BMI and energy intake, fat and fibre. Nutritional status 
was reported to related to a series of factors, such as, level of malabsortion, 
persistent damage in the gastrointestinal tract, anxiety and depression, length 
of time that the patients has lived with untreated CD and nutritional adequacy 
of GFD (Niewinski, 2008; Häuser et al., 2010). Therefore, alterations in BMI 
values may occur after alterations in the absorptive function of the intestinal 
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mucosa and in the patient diet and GFD introduction (Kabbani et al., 2012; 
Kinsey et al., 2008; Moreno et al., 2014). 
5.4. Symptoms before and after GFD adherence 
Improvement in CD patients has been shown to occur in few weeks after 
gluten exclusion (Osman et al., 2014). However, many patients can continue 
to experience clinical manifestations or symptoms related to CD while 
consume a GFD. This clinical event is characterized by several distinct 
diagnoses and it is known as non-responsive celiac (Leffler et al., 2007; Maki, 
2014). The most common reason for this clinical problem is the continued 
dietary exposure to food containing gluten or hypersensitivity to minimal 
amounts of gluten in foods considered as free from gluten (Jadresin et al., 
2008; Comino et al., 2012; Ludvigsson et al., 2014). This evidence is 
analogous to this study, as it was found presence of symptoms in 82.6% of 
the patients who are on a GFD, and both compliant and non-compliant 
patients reported these symptoms. The persistent symptoms most reported by 
compliant were nausea, vomiting and mouth ulcers, and most mentioned by 
noncompliant were fatigue, vomiting, nausea and diarrhoea. However, the 
number of compliant (59) patients who reported has not had any symptoms 
were very higher compared to non-compliant (13). Pulido et al., (2013) who 
studied both symptom recovery and clinical features of 5912 adults coeliac 
patients found similar results. They showed that 80% of them admitted 
symptoms with a median duration of 24 hour, after introduction of a GFD. 
Furthermore, diarrhoea, abdominal pain, vomiting and bloating comprised the 
list of symptoms most reported. Similarly, results from a study by Murray et al. 
(2004) revealed that despite improvement of symptoms after GFD, 34% of 
215 patients still had diarrhoea, 30% constipation, 9% vomiting or nausea and 
3% abdominal pain. However, the gastrointestinal symptoms decreased 
significantly after compared to before GFD (p<0.0001). Nordstrom et al. 
(2012) following in the same line of research analysed symptoms pre-
treatment and after, such as, flatulence, fatigue, soft stool, joint pain and 
abdominal pain. Pre-treatment and today most common symptoms were the 
same, flatulence and fatigue. The study also showed that despite the patients 
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reported persistent symptoms after GFD, there was an improvement of all 
symptoms reported, except joint pain, and a reduction in missed working days 
as well as in consumption of health care. Sainsbury et al. (2013) evaluated 
the severity of the persistent symptoms after GFD. Results showed that mild 
symptoms were mentioned by 15.9%, moderate by 28.2% and severe by 
20.5% of the patients. Other study besides comparing symptoms before and 
after GFD, they also verified the difference between compliant and non-
compliant in terms of clinical presentation and biochemical indicators, at 1-
year of follow-up. No significant difference was found and poor compliance 
with GFD was highly associated to results of long-term impairment of quality 
of life (Nachman et al., 2010). In another research Nachman et al. (2009) 
demonstrated that strictly compliant patients had significantly better quality of 
life, in terms of persistent symptoms, than moderate compliant patients 
(p<0.0001). Considering all these studies it is important to emphasize that 
persistent symptoms after dietary transgression do not affect all CD patients, 
and it may be important and helpful to the CD patients understand the 
importance of a strict GFD, and   thus recognize the effect of gluten exposure, 
even a small quantity (Pulido et al., 2013). In present study, majority of the 
patients reported symptoms for more than 3 years before being diagnosed 
with CD.  Early age treatment of CD has been related to better compliance to 
GFD, and thus reduction of total illness burden and better quality of physical 
health in adulthood (Kurppa et al., 2010; Schuppan and Zimmer, 2013). 
Although studies suggest that it is necessary greater effort to identify CD early 
and then initiate GFD introduction in order to reduce symptoms that are 
related to CD (Norström et al., 2012), it has been reported that histological 
recovery of intestinal mucosa takes a certain period of time (Haines et al., 
2008). 
5.5. Implications and Limitations   
Findings of this study are in accordance with previous researches related to 
compliance with a GFD and nutritional adequacy of nutrients in CD patients, 
since it was shown a discrepancy between the level the compliance and 
malnutrition among patients. Therefore, results suggest a review of nutritional 
!! ! 47!
recommendation for this group of population, as it is clear that they do not 
have the same clinical features as the general population. Moreover, the 
Codex standard should be stricter regarding the regulation of legislation that 
determines the presence of micronutrients in gluten free foods in a similar 
amount to the foods they are replacing.   
Although it was used the best methods in order to collect dietary intake, they 
may be associated with bias due to their limitations. Since, omission of some 
foods (drinks and fillings) or meal as well as inaccurate evaluation of portions 
consumed can lead to underestimation of nutritional values ingested 
(Shepherd and Gibson, 2013; Halter et al., 2002). Furthermore, Patients may 
be more cautious with their diet during the days of report, which may have 
influenced the nutritional adequacy outcomes in this research, as over-report 
was observed (Biagi et al., 2009). Another limitation found was related to diet 
plan software. The program had lack of gluten free foods in their database, 
and thus, made difficult the process of nutrient analysis of this food group. 
However, even though the limitations had influenced the data, findings of this 
study are very satisfactory as it is consistent with some published studies 
(Butterworth et al., 2004; Biagi et al., 2009). 
5.6. Future Research   
It is still much to be investigated regarding to GFD. One interesting point is to 
understand the mechanism and factors related to high level BMI in CD 
patients who are on a strict GFD. Studies have demonstrated that nutritional 
support and follow-up need to be improved, so, should be explored what 
difficulties are faced by the health professionals and identify possible 
interventions. Nutritional inadequacy has been indicated as one of the major 
cause of complications in CD, and there is few studies addressing this issue. 
This shows that greater attention should be given to this issue and further 
studies should be done. 
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6.  CONCLUSION 
In conclusion, despite this study has found high percentage of compliant 
patients, presence of nutritional deficiency and persistent symptoms were 
verified amongst those patients. This shows that all facets of the disease, not 
only gluten avoidance, should be should be analysed when is addressing 
about the treatment of celiac disease. As evidence has shown that the key 
aspects for the success of CD treatment, which includes a good compliance 
with a GED and a better quality of life, are medical support, the understanding 
the factors related to GFD adherence and find possible solutions and nutrition 
education. 
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8. APPENDICES 
8.1. APPENDIX 01: Compliance questionnaires. 
 
Questionnaires:  
Instruction for filling the form: (Please read these carefully before you 
complete the form)  
1. Please circle or tick the relevant option(s) 
2. Where appropriate you may select more than one option 
3. Please do not leave any question blank 
4. If you do not know the answer, please write “don’t know” or “DK” 
5. Please post the questionnaire back to us in the envelope provided.  
Part A:  
1. Sex   Male    Female 
2. Age 
18–30   31–40   41–50  
 51–60   more than 60 
3. Which ethnic group do you belong too? 
European  Muslim   Sikh   Hindu  
4. Are you a vegetarian? 
Yes   No 
5. At what age were you diagnosed by the hospital to be suffering from 
coeliac disease? 
18–30   31–40   41–50   51–60  
 more than 60 
6. Did you have health problems in childhood? 
Yes    No 
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6. What prompted you to consult your General Practitioner (GP)? 
[Please tick relevant option(s)] 
7.  
Fatigue/ Hair loss     Stomach pains/ bloating / Skin 
rash  
Poor appetite/ Diarrhoea     Nausea/Vomiting 
/Mouth ulceration 
Weight loss /Family history    Joint pains /Difficulty 
walking 
8. How long had you been experiencing symptoms before you were 
diagnosed? 
Less than 6 months  6 months to 1 year  1 year to 3 years  more than 
3 years 
9. Did you know what coeliac disease was before you were diagnosed?     
 Yes    No 
10. At the time of your diagnosis, what was discussed at your 
consultation with your hospital doctor? [Please tick relevant option(s)] 
Explained what coeliac disease was   Told me to follow a strict 
gluten-free diet 
Referred me to a dietician    Arranged a follow-up appointment 
Gave written information    Other (please state) 
 
 
 
 
 
!
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11. Were you satisfied with the information given? 
Yes     No 
12. If you were referred to a dietician, what advice were you given? 
[Please tick relevant option(s)] 
Explained the diagnosis and the reasons for the dietARTICLE IN PRESS 
Discussed a gluten-free diet      
Discussed the Coeliac Society and local groups 
Provided an information pack (containing diet sheet, food list, starter packs 
etc) 
Discussed the prescribing of gluten-free products    
A follow-up appointment was made 
Given a contact telephone number for advice, if needed 
13. Were you satisfied with the information given? 
Yes   No 
If “No”, please state why:  
 
 
 
 
 
14. Do you think the dietician should play an important role in the long-
term management of Coeliac Disease? 
Yes     No 
15. How often do you include gluten-containing foods in your diet? 
!
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Never  Once a month  Once a week   Daily  
 Other please specify 
16. What difficulties do you have in following a gluten-free diet? [Please 
tick relevant option(s)] 
I don’t understand what foods I can and cannot eat 
I don’t have the time to prepare different meals 
Gluten-free foods have an unpleasant taste 
Gluten-free foods are expensive to buy 
My GP does not prescribe sufficient amounts of gluten-free products 
I don’t feel any different on a gluten-free diet 
I don’t understand the labelling on foods 
17. Do you have symptoms when you eat food containing gluten? 
Yes   No 
If yes, what symptoms do you experience? [Please tick relevant 
option(s)] 
Nausea/vomiting Stomach pains   Diarrhoea Fatigue/tiredness 
Mouth ulcers      Others (please specify) 
18. Do you get gluten-free products on prescription? 
Yes       No 
If No, did you know that they are available on prescription? 
Yes       No 
If yes, do you get sufficient amounts of gluten-free products on 
prescription? 
Yes       No 
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19. Are you a member of the Coeliac Society? 
Yes (please go to question 20)    No 
If you are not a member, is it because:- [please tick relevant option(s)] 
You didn’t know about it 
 
You have a contact address, but haven’t joined yet 
You don’t feel it is important 
If I need advice, I will ask my GP 
Other (please specify 
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Part B:  
Please circle one option for each question in the columns from 1 to 5.  
 
Thank you for completing the questionnaire. Please use the enclosed 
stamped addressed envelope to return it to us. 
Dr H Muhammad Questionnaire Version 1 30/06/2015 
Questions 1 2 3 4 5 
Have you been 
bothered by low 
energy level during 
the past 4 weeks? 
 
None of 
the 
time 
 
A little of 
the time 
Some of the 
time 
 
Most of 
the time 
All of the 
time 
Have you been 
bothered by 
headaches during the 
past 4 weeks? 
 
None of 
the 
time 
 
A little of 
the time 
Some of the 
time 
 
Most of 
the time 
All of the 
time 
I am able to follow a 
GFD when dining 
outside my home 
 
Strongly 
agree 
Somewhat 
agree 
Neither agree 
nor disagree 
 
Somewhat 
disagree 
Strongly 
disagree 
Before I do something 
I carefully consider 
the consequences 
 
Strongly 
agree 
Somewhat 
agree 
Neither agree 
nor disagree 
 
Somewhat 
disagree 
Strongly 
disagree 
I do not consider 
myself a failure 
Strongly 
agree 
Somewhat 
agree 
Neither agree 
nor disagree 
 
Somewhat 
disagree 
Strongly 
disagree 
How important to your 
health are 
accidental gluten 
exposures? 
 
Very 
important 
Somewhat 
important 
Neutral/unsure A little 
important 
Not at all 
important 
Over the past 4 
weeks, how many 
times have you eaten 
foods  containing 
gluten on purpose? 
 
0-never 1-2 3-5 6-10 >10 
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8.2. APPENDIX 02: Food diaries form example. 
 
Food Diary  
Please circle: Monday Tuesday Wednesday Thursday Friday Saturday 
Sunday  
 Food  
Amount 
(e.g., 
tbsp, 
can, 
serving
)  
Time  Where and Who with  Thoughts  
 
   
  
   
   
   
   
 
   
     
   
 
   
  
   
   
   
   
   
 
   
     
   
 
   
  
   
   
   
   
   
   
   
Total 
number 
of 5 A 
Day 
portion
s  
 Have I reached my target?   
 
World Cancer Research Fund (WCRF UK) 22 Bedford Square, London 
WC1B 3HH Tel: 020 7343 4200 Web: www.wcrf-uk.org Breakfast Mid 8.3. 
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8.3. APPENDIX 03: Ethical approval letters 
 
 
 
27 November 2014  
Dr Humayun Muhammad University Hospital of Leicester Leicester General 
Hospital Gwendolen Rd, Leicester  
LE5 4PW  
Dear Dr Muhammad  
Study title:  
REC reference: Protocol number: IRAS project ID:  
National Research Ethics Service  
NRES Committee London - Queen Square  
HRA NRES Centre Manchester Barlow House 3rd Floor 4 Minshull Street 
Manchester M1 3DZ  
An investigation into dietary compliance of patients with coeliac 
disease 14/LO/2128 CD/RU/01  
159160  
The Proportionate Review Sub-committee of the NRES Committee London - 
Queen Square reviewed the above application on 20 November 2014.  
We plan to publish your research summary wording for the above study on 
the HRA website, together with your contact details, unless you expressly 
withhold permission to do so. Publication will be no earlier than three months 
from the date of this favourable opinion letter. Should you wish to provide a 
substitute contact point, require further information, or wish to make a request 
to postpone publication, please contact the REC Manager Rachel Heron, 
nrescommittee.london-queensquare@nhs.net.  
Ethical opinion  
On behalf of the Committee, the sub-committee gave a favourable ethical 
opinion of the above research on the basis described in the application form, 
protocol and supporting documentation, subject to the conditions specified 
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below.  
Conditions of the favourable opinion  
The favourable opinion is subject to the following conditions being met prior to 
the start of the study.  
1. Please provide an explanation as to why the research will not be registered 
on a public database (Q50, page 14 of the IRAS form).   
2. Participant Information A Research Ethics Committee established by the 
Health Research Authority   
. a)  Please make it explicit in both the Participant Information Sheet and 
Consent form that this research is being carried out as part of a PHD.   
. b)  On the Patient Information Sheet, the total approximate time required to 
complete the questionnaires should be reported: e.g. “Completing 
these questionnaires takes approximately 20 minutes in total”. This 
sentence could be added to the “What are the possible disadvantages 
and risks of taking part?” section.   
. c)  The Committee suggests adding the following sentence or similar to the 
section entitled ‘What are the possible disadvantages and risks of 
taking part’: “Some of the questions in the questionnaires may be of a 
sensitive nature. All information you give will be kept confidential. If you 
have any concerns, please do not hesitate to contact us."   
. d)  It should be clear on the patient information whether participants have to 
answer all the questions in the questionnaire, or whether they can omit 
some and still participate in the study.   
Consent forms  
a) The following sentence (“this information will always be anonymised”) 
should be added as shown here in capitals: “I understand that any information 
given by me may be used in future reports, articles or presentations by the 
research team. THIS INFORMATION WILL ALWAYS BE ANONYMISED. My 
General Practitioner GP may be contacted by the researcher.”  
Invitation letter  
a) For clarity, please add “(fifty pounds)” as shown here in capital letters: 
“There is a prize draw of £50.00 (FIFTY POUNDS) high street vouchers for 
participating in this study.”  
Please also proof read material so that typos and minor errors are minimised.  
You should notify the REC in writing once all conditions have been met 
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(except for site approvals from host organisations) and provide copies of any 
revised documentation with updated version numbers. The REC will 
acknowledge receipt and provide a final list of the approved documentation for 
the study, which can be made available to host organisations to facilitate their 
permission for the study. Failure to provide the final versions to the REC may 
cause delay in obtaining permissions.  
Management permission or approval must be obtained from each host 
organisation prior to the start of the study at the site concerned.  
Management permission (“R&D approval”) should be sought from all NHS 
organisations involved in the study in accordance with NHS research 
governance arrangements.  
Guidance on applying for NHS permission for research is available in the 
Integrated   
A Research Ethics Committee established by the Health Research Authority  
Research Application System or at http://www.rdforum.nhs.uk.  
Where a NHS organisation’s role in the study is limited to identifying and 
referring potential participants to research sites (“participant identification 
centre”), guidance should be sought from the R&D office on the information it 
requires to give permission for this activity.  
For non-NHS sites, site management permission should be obtained in 
accordance with the procedures of the relevant host organisation.  
Sponsors are not required to notify the Committee of approvals from host 
organisations. Registration of Clinical Trials  
All clinical trials (defined as the first four categories on the IRAS filter page) 
must be registered on a publically accessible database within 6 weeks of 
recruitment of the first participant (for medical device studies, within the 
timeline determined by the current registration and publication trees).  
There is no requirement to separately notify the REC but you should do so at 
the earliest opportunity e.g. when submitting an amendment. We will audit the 
registration details as part of the annual progress reporting process.  
To ensure transparency in research, we strongly recommend that all research 
is registered but for non-clinical trials this is not currently mandatory.  
If a sponsor wishes to contest the need for registration they should contact 
Catherine Blewett (catherineblewett@nhs.net), the HRA does not, however, 
expect exceptions to be made. Guidance on where to register is provided 
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within IRAS.  
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular site 
(as applicable).  
Ethical review of research sites  
The favourable opinion applies to all NHS sites taking part in the study, 
subject to management permission being obtained from the NHS/HSC R&D 
office prior to the start of the study (see “Conditions of the favourable 
opinion”).  
Summary of discussion at the meeting  
Social or scientific value; scientific design and conduct of the study  
The Committee queried why the research would not be registered on a public 
database.  
Informed consent process and the adequacy and completeness of research 
participant information  
The Committee felt that it should have been made clearer that information 
would be anonymised if used in future reports, articles or presentations.  
The Committee noted a few minor points which needed to be clarified on the 
participant information sheets, which are listed above.   
A Research Ethics Committee established by the Health Research Authority  
Suitability of supporting information  
The Commiittee noted that there was one area of clarification to be made on 
the invitation letter regarding payment.  
Approved documents  
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The documents reviewed and approved were:  
Document  Version  Date  
Evidence of Sponsor insurance or indemnity (non 
NHS Sponsors only)   
12 August 2014  
IRAS Checklist XML [Checklist_14112014]   14 November 2014  
Letter from sponsor   21 October 2014  
Letters of invitation to participant  2  01 October 2014  
Other [CV S Reeves]    
Other [CV John Mayberry]    
Other [Permission from Dr Cooper to use 
questionnaire]   
14 May 2014  
Other [Permission from Dr Leffler to use 
questionnaire]   
05 November 2014  
Other [Food diary]    
Participant consent form  2  14 October 2014  
Participant information sheet (PIS)  2  01 October 2014  
REC Application Form [REC_Form_14112014]   14 November 2014  
Research protocol or project proposal  2  01 October 2014  
Summary CV for Chief Investigator (CI)    
Summary CV for supervisor (student research)    
Summary, synopsis or diagram (flowchart) of 
protocol in non technical language  
2  01 October 2014  
Validated questionnaire    30 June 2014  
 
Membership of the Proportionate Review Sub-Committee  
The members of the Sub-Committee who took part in the review are listed on 
the attached sheet.  
Statement of compliance  
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The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees and complies fully with the 
Standard Operating Procedures for Research Ethics Committees in the UK.  
After ethical review  
Reporting requirements  
The attached document “After ethical review – guidance for researchers” 
gives detailed guidance on reporting requirements for studies with a 
favourable opinion, including:  
  ·   Notifying substantial amendments   
  ·   Adding new sites and investigators   
  ·   Notification of serious breaches of the protocol   
A Research Ethics Committee established by the Health Research Authority  
  ·   Progress and safety reports   
  ·   Notifying the end of the study  The HRA website also provides 
guidance on these topics, which is updated in the light of changes in 
reporting requirements or procedures.  User Feedback  The Health 
Research Authority is continually striving to provide a high quality 
service to all applicants and sponsors. You are invited to give your view 
of the service you have received and the application procedure. If you 
wish to make your views known please use the feedback form 
available on the HRA website: http://www.hra.nhs.uk/about-the- 
hra/governance/quality-assurance/  HRA Training  We are pleased to 
welcome researchers and R&D staff at our training days – see details 
at http://www.hra.nhs.uk/hra-training/  With the Committee’s best 
wishes for the success of this project.  Yours sincerely  On behalf of 
Gella Richards Vice Chair  Email: nrescommittee.london-
queensquare@nhs.net  Enclosures: List of names and professions of 
members who took part in the review “After ethical review – guidance 
for researchers” [SL-AR2]  Copy to: Mrs Jan Harrison Mrs Carolyn 
Maloney, University Hospitals of Leicester NHS Trust.                     
Dear Humayun, 
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Ethics Application 
Applicant:                    Humayun Muhammad 
Title:                            An investigation into dietary compliance of 
patients with Coeliac Disease 
Reference:                    LSC 14/ 112 
Department:                 Life Sciences 
  
I have been advised that your above project has now received NHS REC 
approval (subject to conditions) - congratulations. Please note that it is your 
responsibility to meet any conditions imposed by the NHS in respect of this 
application. Please let us have the revised documentation in relation to the 
conditions imposed by them so that we can also confirm the amendments.   
  
Condition: 
Please advise us once NHS R&D approval have been received 
  
Many thanks, 
  
Jan 
Jan Harrison Ethics Officer, Research Office, Department of Academic 
Enhancement University of Roehampton | London | SW15 5PJ 
jan.harrison@roehampton.ac.uk| www.roehampton.ac.uk 
Tel: +44 (0) 20 8392 5785 
Follow us on Twitter | Find us on Facebook Join our circle on Google+ | 
Connect via LinkedIn 
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8.3. APPENDIX 04: Descriptive data. 
 
Descriptive Statistics 
 N Minimum Maximum Mean Std. Deviation 
Unique Patient ID 86 8 716 434.30 232.363 
Gender 86 1 2 1.73 .445 
what is the age of the 
patient 
86 19 64 46.44 14.505 
Which group do you 
belong to 
86 0 4 1.06 .416 
in Kgs 86 66.50 85.10 74.4523 4.42692 
cm 86 157.00 177.00 164.9698 6.06116 
Energyintake 86 636.00 2549.00 1390.2558 373.25784 
BMI 86 22.60 31.50 27.4674 1.82166 
Valid N (listwise) 86     
 
 
 
Which group do you belong to 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
0 1 1.2 1.2 1.2 
1 82 95.3 95.3 96.5 
2 1 1.2 1.2 97.7 
3 1 1.2 1.2 98.8 
4 1 1.2 1.2 100.0 
Total 86 100.0 100.0  
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8.4. APPENDIX 05: Descriptive data by compliance groups. 
 
Descriptive  
Descriptive Statisticsa 
 N Minimum Maximum Mean Std. Deviation 
Gender 71 1 2 1.76 .430 
what is the age of the 
patient 
71 19 64 47.18 14.255 
Which group do you 
belong to 
71 0 4 1.03 .377 
in Kgs 71 68.40 85.10 74.5620 4.34286 
cm 71 157.00 177.00 164.5338 5.92947 
Energyintake 71 727.00 2549.00 1400.4085 364.48827 
Unique Patient ID 71 8 716 447.03 228.108 
Valid N (listwise) 71     
a. Compliancegroup = Compliant 
 
Descriptive Statisticsa 
 N Minimum Maximum Mean Std. 
Deviation 
Gender 15 1 2 1.60 .507 
what is the age of the 
patient 
15 21 64 42.93 15.664 
Which group do you 
belong to 
15 1 3 1.20 .561 
in Kgs 15 66.50 83.50 73.9333 4.93293 
cm 15 159.50 176.00 167.0333 6.45995 
Energyintake 15 636.00 2355.00 1342.2000 422.63987 
Unique Patient ID 15 56 710 374.07 250.874 
Valid N (listwise) 15     
a. Compliancegroup = Non-cpmpliant 
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5.5. APPENDIX 06: Data of level compliance, percentage of GFD on 
prescription, and frequency of consumption of products 
containing gluten. 
Statisticsa 
This is total leffler score, if 
above 19, the patient is strongly 
non-compliant   
N 
Valid 71 
Missing 0 
Mean 12.0563 
Std. Deviation 2.42539 
a. Compliancegroup = 
Compliant 
 
Statisticsa 
This is total leffler score, if 
above 19, the patient is strongly 
non-compliant   
N 
Valid 15 
Missing 0 
Mean 20.1333 
Std. Deviation 3.15926 
a. Compliancegroup = Non 
cpmpliant 
 
 
Descriptive Statistics 
 N Minimum Maximum Mean Std. Deviation 
This is total leffler score, if 
above 19, the patient is 
strongly non-compliant 
86 7.00 28.00 13.4651 3.99911 
Valid N (listwise) 86     
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Do you get gluten-free products on prescription? 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
No 30 34.9 34.9 34.9 
Yes 54 62.8 62.8 97.7 
2 2 2.3 2.3 100.0 
Total 86 100.0 100.0  
 
How often do you include gluten-containing foods in your diet? 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
0 3 3.5 3.5 3.5 
Never 60 69.8 69.8 73.3 
Once a month 13 15.1 15.1 88.4 
Once a week 3 3.5 3.5 91.9 
daily 5 5.8 5.8 97.7 
Other 2 2.3 2.3 100.0 
Total 86 100.0 100.0  
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5.6. APPENDIX 07: Difference test for age, gender, ethnicity, weight, 
GFD on prescription and frequency of consumption of products 
containing gluten on diet between compliant and non-compliant  
 
Frequencies:  
How often do you include gluten containing foods in your diet?a 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
0 3 4.2 4.2 4.2 
Never 52 73.2 73.2 77.5 
Once a month 9 12.7 12.7 90.1 
Once a week 2 2.8 2.8 93.0 
daily 3 4.2 4.2 97.2 
Other 2 2.8 2.8 100.0 
Total 71 100.0 100.0  
a. Compliancegroup = Compliant 
 
 
 
Gendera 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
Male 17 23.9 23.9 23.9 
Female 54 76.1 76.1 100.0 
Total 71 100.0 100.0  
a. Compliancegroup = Compliant 
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Which group do you belong toa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
1 13 86.7 86.7 86.7 
2 1 6.7 6.7 93.3 
3 1 6.7 6.7 100.0 
Total 15 100.0 100.0  
a. Compliancegroup = Non-cpmpliant 
 
Do you get gluten-free products on prescription?a 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
No 24 33.8 33.8 33.8 
Yes 45 63.4 63.4 97.2 
2 2 2.8 2.8 100.0 
Total 71 100.0 100.0  
a. Compliancegroup = Compliant 
 
How often do you include gluten containing foods in your diet?a 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
Never 8 53.3 53.3 53.3 
Once a month 4 26.7 26.7 80.0 
Once a week 1 6.7 6.7 86.7 
daily 2 13.3 13.3 100.0 
Total 15 100.0 100.0  
a. Compliancegroup = Non-cpmpliant 
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Gendera 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
Male 6 40.0 40.0 40.0 
Female 9 60.0 60.0 100.0 
Total 15 100.0 100.0  
a. Compliancegroup = Non-cpmpliant 
 
Which group do you belong toa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
1 13 86.7 86.7 86.7 
2 1 6.7 6.7 93.3 
3 1 6.7 6.7 100.0 
Total 15 100.0 100.0  
a. Compliancegroup = Non-cpmpliant 
 
Do you get gluten-free products on prescription?a 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
No 6 40.0 40.0 40.0 
Yes 9 60.0 60.0 100.0 
Total 15 100.0 100.0  
a. Compliancegroup = Non-cpmpliant 
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Mann-Whitney Test 
Test Statisticsa 
 what is the age 
of the patient 
in Kgs 
Mann-Whitney U 464.500 486.500 
Wilcoxon W 584.500 606.500 
Z -.775 -.524 
Asymp. Sig. (2-tailed) .439 .600 
a. Grouping Variable: Compliancegroup 
 
 
Statisticsa 
 what is the age 
of the patient 
in Kgs 
N 
Valid 71 71 
Missing 0 0 
Median 51.00 73.7000 
Range 45 16.70 
a. Compliancegroup = Compliant 
 
Statisticsa 
 what is the age 
of the patient 
in Kgs 
N 
Valid 15 15 
Missing 0 0 
Median 42.00 72.7000 
Range 43 17.00 
a. Compliancegroup = Non-cpmpliant 
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8.5. APPENDIX 08: Dietary intake and meeting RNI-intake of 
micronutrients data 
 
Descriptive Statistics 
 N Minimum Maximum Mean Std. Deviation 
Energyintake 86 636.00 2549.00 1390.2558 373.25784 
Protein 86 22.70 115.10 51.2570 13.38587 
Fat 86 20.10 114.40 54.1198 18.14885 
Carbs 86 77.90 391.30 168.8198 55.53001 
Fibre 86 5.30 31.70 14.5105 5.36483 
VitaminB6 86 .31 2.60 1.1658 .40761 
VintaminB12 86 .20 26.60 2.9605 2.98286 
Folate 86 38.00 493.00 157.8488 76.89650 
Iron 86 1.76 15.74 6.0466 2.87083 
Calcium 86 103.00 2046.00 492.1977 257.62886 
Fiberdensity 86 .44 2.30 1.0633 .35455 
Valid N (listwise) 86     
 
FibermeetingRNI 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
1.00 4 4.7 4.7 4.7 
2.00 82 95.3 95.3 100.0 
Total 86 100.0 100.0  
 
VitaminB6meetingRNI 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 30 34.9 34.9 34.9 
no 56 65.1 65.1 100.0 
Total 86 100.0 100.0  
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VitamingB12meetingRNI 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 58 67.4 67.4 67.4 
no 28 32.6 32.6 100.0 
Total 86 100.0 100.0  
 
FolatemeetingRNI 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 1 1.2 1.2 1.2 
no 85 98.8 98.8 100.0 
Total 86 100.0 100.0  
 
 
 
 
IronmeetingRNI 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 14 16.3 16.3 16.3 
no 72 83.7 83.7 100.0 
Total 86 100.0 100.0  
 
CalciummeetingRNI 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 3 3.5 3.5 3.5 
no 83 96.5 96.5 100.0 
Total 86 100.0 100.0  
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APPENDIX 09: Difference test in nutrients intake between groups 
 
Test Statisticsa 
 Energyintake Protein Fat Carbs 
Mann-Whitney U 469.000 410.000 459.500 508.500 
Wilcoxon W 589.000 530.000 3015.500 628.500 
Z -.723 -1.394 -.831 -.273 
Asymp. Sig. (2-tailed) .470 .163 .406 .785 
a. Grouping Variable: Compliancegroup 
 
Test Statisticsa 
 Fibermeet
ingRNI 
VitaminB6
meetingRNI 
VitamingB12
meetingRNI 
Fiberdensity 
Mann-Whitney U 502.500 522.500 494.500 341.000 
Wilcoxon W 3058.500 3078.500 614.500 461.000 
Z -.936 -.138 -.533 -2.180 
Asymp. Sig. (2-tailed) .349 .890 .594 .029 
a. Grouping Variable: Compliancegroup 
 
 
 
 
Test Statisticsa 
 Fibre VitaminB6 VintaminB12 Folate Iron Calcium 
Mann-Whitney U 376.500 504.000 469.000 476.500 449.000 381.500 
Wilcoxon W 
496.500 624.000 3025.000 596.500 3005.00
0 
501.500 
Z -1.776 -.324 -.723 -.637 -.950 -1.718 
Asymp. Sig. (2-
tailed) 
.076 .746 .470 .524 .342 .086 
a. Grouping Variable: Compliancegroup 
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Test Statisticsa 
 Folatemeeting
RNI 
IronmeetingRN
I 
Calciummeetin
gRNI 
Mann-Whitney U 525.000 465.500 510.000 
Wilcoxon W 3081.000 585.500 3066.000 
Z -.460 -1.192 -.806 
Asymp. Sig. (2-tailed) .646 .233 .420 
a. Grouping Variable: Compliancegroup 
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8.6. APPENDIX 10: APPENDIX 09: Difference in micronutrients 
meeting RNI-intake between groups. 
FibermeetingRNIa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
1.00 4 5.6 5.6 5.6 
2.00 67 94.4 94.4 100.0 
Total 71 100.0 100.0  
a. Compliancegroup = Compliant 
 
VitamingB12meetingRNIa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 47 66.2 66.2 66.2 
no 24 33.8 33.8 100.0 
Total 71 100.0 100.0  
a. Compliancegroup = Compliant 
 
VitaminB6meetingRNIa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 25 35.2 35.2 35.2 
no 46 64.8 64.8 100.0 
Total 71 100.0 100.0  
a. Compliancegroup = Compliant 
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FolatemeetingRNIa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 1 1.4 1.4 1.4 
no 70 98.6 98.6 100.0 
Total 71 100.0 100.0  
a. Compliancegroup = Compliant 
 
CalciummeetingRNIa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 3 4.2 4.2 4.2 
no 68 95.8 95.8 100.0 
Total 71 100.0 100.0  
a. Compliancegroup = Compliant 
 
IronmeetingRNIa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 10 14.1 14.1 14.1 
no 61 85.9 85.9 100.0 
Total 71 100.0 100.0  
a. Compliancegroup = Compliant 
 
FibermeetingRNIa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 2.00 15 100.0 100.0 100.0 
a. Compliancegroup = Non-cpmpliant 
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VitaminB6meetingRNIa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 5 33.3 33.3 33.3 
no 10 66.7 66.7 100.0 
Total 15 100.0 100.0  
a. Compliancegroup = Non-cpmpliant 
 
 
VitamingB12meetingRNIa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 11 73.3 73.3 73.3 
no 4 26.7 26.7 100.0 
Total 15 100.0 100.0  
a. Compliancegroup = Non-cpmpliant 
 
FolatemeetingRNIa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid no 15 100.0 100.0 100.0 
a. Compliancegroup = Non-cpmpliant 
 
IronmeetingRNIa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
yes 4 26.7 26.7 26.7 
no 11 73.3 73.3 100.0 
Total 15 100.0 100.0  
a. Compliancegroup = Non-cpmpliant 
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CalciummeetingRNIa 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid no 15 100.0 100.0 100.0 
a. Compliancegroup = Non-cpmpliant 
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8.7. APPENDIX 11: Correlations analysis for BMI and fat, fibre and 
energy intake, data of mean BMI and differences in BMI 
between compliance groups. 
 
Correlations 
 BMI Fat Fibre 
Spearman's rho 
BMI 
Correlation Coefficient 1.000 .241* .220* 
Sig. (2-tailed) . .026 .041 
N 86 86 86 
Fat 
Correlation Coefficient .241* 1.000 .288** 
Sig. (2-tailed) .026 . .007 
N 86 86 86 
Fibre 
Correlation Coefficient .220* .288** 1.000 
Sig. (2-tailed) .041 .007 . 
N 86 86 86 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
Correlations 
 Energyintake BMI 
Energyintake 
Pearson Correlation 1 .304** 
Sig. (2-tailed)  .004 
N 86 86 
BMI 
Pearson Correlation .304** 1 
Sig. (2-tailed) .004  
N 86 86 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Descriptive Statisticsa 
 N Minimum Maximum Mean Std. Deviation 
BMI 71 22.60 31.50 27.6535 1.80070 
Valid N (listwise) 71     
a. Compliancegroup = Compliant 
 
Descriptive Statisticsa 
 N Minimum Maximum Mean Std. Deviation 
BMI 15 23.20 29.40 26.5867 1.71125 
Valid N (listwise) 15     
a. Compliancegroup = Non-cpmpliant 
 
 
Test Statisticsa 
 BMI 
Mann-Whitney U 358.500 
Wilcoxon W 478.500 
Z -1.981 
Asymp. Sig. (2-tailed) .048 
a. Grouping Variable: 
Compliancegroup 
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8.8. APPENDIX 12: Data of symptoms before and after GFD. 
 
Do you have symptoms when you eat food-containing gluten? 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
No 6 7.0 7.0 7.0 
Yes 71 82.6 82.6 89.5 
Not applicable 9 10.5 10.5 100.0 
Total 86 100.0 100.0  
 
 
 
Lenght_SymptomsBF 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid 
0 1 1.2 1.2 1.2 
Less than 6 
months 
11 12.8 12.8 14.0 
6 months to 1 year 16 18.6 18.6 32.6 
1 year to 3 years 25 29.1 29.1 61.6 
More than 3 years 31 36.0 36.0 97.7 
other 2 2.3 2.3 100.0 
Total 86 100.0 100.0  
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8.9. APPENDIX 13: Data of types of symptoms mentioned 
 
Crosstab 
Count   
 Compliancegroup Total 
Compliant Non-cpmpliant 
My symptom after 
ingestion of GFD Nausea 
and vomitting 
No 52 9 61 
Yes 
19 6 25 
Total 71 15 86 
 
Crosstab 
Count   
 Compliancegroup Total 
Compliant Non-cpmpliant 
My symptom after 
ingestion of GFD 
diarrhoea 
No 36 9 45 
Yes 
35 6 41 
Total 71 15 86 
 
Crosstab 
Count   
 Compliancegroup Total 
Compliant Non-cpmpliant 
My symptom after 
ingestion of GFD fatigue 
No 39 11 50 
Yes 32 4 36 
Total 71 15 86 
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Count   
 Compliancegroup Total 
Compliant Non-cpmpliant 
My symptom after 
ingestion of GFD others 
No 50 11 61 
Yes 21 4 25 
Total 71 15 86 
 
Crosstab 
Count   
 Compliancegroup Total 
Compliant Non-cpmpliant 
My symptom after 
ingestion of GFD stomach 
pain 
No 36 6 42 
Yes 
35 9 44 
Total 71 15 86 
 
Crosstab 
Count   
 Compliancegroup Total 
Compliant Non-cpmpliant 
My symptom after 
ingestion of GFD Not 
applibale because i dont 
eat GFD and hence dont 
know 
no 59 13 72 
yes 
12 2 14 
Total 71 15 86 
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Count   
 Compliancegroup Total 
Compliant Non-cpmpliant 
My symptom after 
ingestion of GFD mouth 
ulcers 
No 63 13 76 
Yes 
8 2 10 
Total 71 15 86 
 
 
 
